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ABSTRACT 
 
Objectives: Despite dose-limiting nephrotoxic potentials, polymyxin B has re-
emerged as the last line of therapy against multidrug-resistant Gram-negative 
bacterial infections. However, the pharmacokinetic, pharmacodynamic and 
nephrotoxic properties of polymyxin B are still not thoroughly understood. The 
objectives of this study were to provide additional insights to the overall 
biodistribution and disposition of polymyxin B; to evaluate the impact of renal 
polymyxin B exposure on nephrotoxicity; to delineate the underlying transport 
mechanism(s) responsible for the intrarenal drug accumulation. 
 
 Methods: A comparative pharmacokinetic profile of various polymyxin B 
components following intravenous administration was derived in rats. The overall 
drug biodistribution in various organs (brain, heart, lungs, liver, spleen, kidneys 
and skeletal muscle) was assessed. Intrarenal distribution of polymyxin B was 
evaluated at the cellular level. Drug disposition was quantified in rat urine/ bile. 
Renal drug accumulation was assessed at different polymyxin B dosing levels, 
and the onset of polymyxin B-induced nephrotoxicity was correlated to the renal 
drug exposure. The role of megalin, a renal endocytic receptor was evaluated in 
the renal accumulation of polymyxin B. 
 viii 
 
Results: The pharmacokinetic profiles of individual polymyxin B components 
were comparable. Among all the organs evaluated, polymyxin B distribution was 
highest in the kidneys. Within kidneys, the highest drug accumulation was 
observed in the proximal tubular cells. Less than 5% of administered dose (or 
pharmacologically active metabolites, if any) were recovered in the urine over 48 
h, but all four major polymyxin B components were detected in the bile over 4 h. 
The higher daily dose of polymyxin B resulted in greater renal accumulation. The 
onset of nephrotoxicity was correlated to the daily dose of polymyxin B. The 
megalin-mediated renal uptake of polymyxin B could be disrupted. 
 
Conclusions: The individual components of polymyxin B demonstrate similar 
pharmacokinetics. The biodistribution findings corroborate our previous results 
that polymyxin B is highly accumulated in the kidneys, but the elimination is likely 
via a non-renal route. Biliary excretion could be one of the possible routes of 
polymyxin B elimination, which should be further explored. The onset of polymyxin 
B-induced nephrotoxicity is correlated to the renal drug exposure.  In addition, 
megalin appears to play a pivotal role in the renal accumulation of polymyxin B, 
which might contribute to nephrotoxicity. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
      The emergence of antimicrobial resistance is a major global public health 
crisis (Chen, Ko, & Hsueh, 2013; Clark, Zhanel, & Lynch, 2016; Zavascki, 
Goldani, Li, & Nation, 2007). Gram-negative bacilli, in particular, present with 
high levels of intrinsic resistance and a tendency to acquire additional modes of 
resistance. Thus, they are formidable pathogens commonly implicated in 
nosocomial infections (Ali, Mumtaz, Naz, Jabeen, & Shafique, 2015; Artiaco, 
Cicero, Bellomo, & Bianchi, 2012; Bergamasco et al., 2012). These infections are 
associated with high risk of mortality and morbidity (Alp, Coruh, Gunay, Yontar, & 
Doganay, 2012; Baijal et al., 2014; Lye et al., 2012; Tumbarello et al., 2015). As 
a result of the escalating multidrug-resistance (MDR) among these pathogens, 
many currently available antibiotics used for these infections are rendered 
ineffective. Furthermore, there are few antibacterial agents in the advanced 
stages of the drug development process against this ensemble of resistant 
pathogens. Under these dire circumstances, it has become increasingly 
challenging to treat these life-threatening infections, particularly in intensive care 
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unit settings where multidrug-resistant Gram-negative bacilli are highly prevalent 
(Costa Pde, Atta, & Silva, 2015; Lye et al., 2012; Pradhan, Bhat, & Ghadage, 
2014). In response to this clinical need, there has been a resurgence of old 
antibiotics, such as the polymyxins, as the last treatment resort against infections 
caused by multidrug-resistant Gram-negative pathogens (Arnold, Forrest, & 
Messmer, 2007; Bergen, Landersdorfer, Lee, Li, & Nation, 2012; Zavascki et al., 
2007). 
 
1.1.1 Agents of Last Resort  
Polymyxins [polymyxin B and polymyxin E (colistin)] are increasing used 
as a last-line option for the treatment of MDR Gram-negative bacteria. 
Polymyxins are cyclic polypeptide antibiotics introduced for clinical use in the 
1950s. However, their use diminished considerably in the early 1970s due to 
nephrotoxicity concerns (Keirstead et al., 2014; Nandha, Sekhri, & Mandal, 2013; 
Ouderkirk, Nord, Turett, & Kislak, 2003). Despite being available for over 50 
years, the correlation between the pharmacokinetics and toxicodynamic profiles 
of polymyxin B is still not thoroughly understood. We have very limited 
information regarding in vivo biodistribution, cellular disposition, elimination 
pathways and transport characteristics of polymyxin B. This knowledge gap often 
hinders the optimal clinical use of polymyxin B. Therefore, studies to delineate 
 3 
 
the pharmacokinetic, pharmacodynamic and toxicodynamic profiles of polymyxin 
B are warranted. Undoubtedly, such information will play a pivotal role in 
designing optimal polymyxin B dosing strategies, which will maximize the clinical 
efficacy as well as safety for its use. 
 
 
1.1.2 Chemistry and Structure 
       Polymyxins are amphiphilic cationic polypeptide antibiotics isolated from 
various strains of Bacillus polymyxa. Polymyxin B and polymyxin E (colistin) are 
the only two clinically used antibiotics from this class and they are active against 
a wide spectrum of Gram-negative bacteria. Commercially available polymyxin B 
is a mixture of several structurally related cyclic amphiphilic analogs, primarily 
polymyxin B1, B2, B3 and isoleucine B1 (Orwa et al., 2001). The relative 
abundance of each component in the USP mixture is reported to be 61.2%, 
25.4%, 5.6% and 7.7% for polymyxin B1, B2, B3, and isoleucine B1 respectively. 
The proportion of these four primary components in the USP mixture has been 
shown to be relatively consistent among various polymyxin B formulations 
procured from different vendors/ manufacturers (He, Ledesma, et al., 2010).  
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       The basic structure of polymyxins consists of a seven-membered 
polypeptide cationic ring and linear tripeptide chain connected terminally to a 
fatty acyl moiety. The only structural variation that differentiates polymyxin B from 
polymyxin E is the replacement of D-phenylalanine with D-Leucine in the seven-
membered cyclic polycationic ring as shown in Figure 1.1 (A. L. Kwa, Lim, et al., 
2008). Polymyxin B1, B2, and B3, the three major components of the polymyxin 
B mixture vary at the fatty acid terminus. The fatty acid moiety in polymyxin B1 
contains 6-methyloctanoic acid; B2 6-methylheptanoic acid, B3 octanoic acid. 
Isoleucine polymyxin B1 is an isomer of polymyxin B1 where L-leucine is 
replaced L-isoleucine in the cyclic ring as represented in Figure 1.2 (Zavascki, 
Goldani, Li, & Nation, 2007). 
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Figure 1.1: Structures of Various Polymyxins (Orwa et al., 2001) 
A. Polymyxin B 
 
 
 
B.  Polymyxin E (Colistin) 
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Figure 1.2: Structure of Major Components of Polymyxin B (Orwa et al., 
2001) 
 
 
 
Polymyxin Fatty acid (FA) Amino acid (X) Molecular weight 
PMB1 6-methyloctanoic acid L-leucine 1202 
Ile-PMB1 6-methyloctanoic acid L-isoleucine 1202 
PMB2 6-methylheptanoic acid L-leucine 1188 
PMB3 Octanoic acid L-leucine 1188 
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1.1.3 Commercial Formulation and Route of Administration 
      Polymyxin B is primarily formulated as a sulfate salt and administered 
parenterally. Colistin, however, is formulated as colistin sulfate and colistimethate 
sodium for oral, topical and parenteral use. Colistin is administered parenterally 
as colistimethate sodium, a prodrug of colistin which undergoes hydrolysis in 
plasma to the pharmacologically active moiety (Bergen, Li, Rayner, & Nation, 
2006). Colistin sulfate is administered both orally and topically (A. Kwa, 
Kasiakou, Tam, & Falagas, 2007). 
 
1.1.4 Spectrum of Activity 
Polymyxin B and colistin are reported to exhibit comparable 
pharmacodynamic activity (Tam, Cao, Ledesma, & Hu, 2011). They have an 
identical spectrum of activity which includes most Gram-negative bacilli, such as 
Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter 
baumannii, which are intrinsically susceptible to polymyxins. Various 
Enterobacteriaceae, such as Escherichia coli, Salmonella spp., Shigella spp., 
and Klebsiella spp. are resistant to a large variety of antibiotics but are 
susceptible to polymyxins. Additionally, polymyxins possess potent antibacterial 
activity against Neisseria spp., Haemophilus influenzae and Bordetella pertussis. 
However, polymyxins lack activity against Gram-positive bacteria, anaerobic 
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bacteria, and fungi (A. L. Kwa, Tam, & Falagas, 2008; Yuan & Tam, 2008; 
Zavascki et al., 2007). 
 
 
1.1.5  In vitro susceptibility of Polymyxins in Clinical Isolates 
To date, the most elaborately compiled data evaluating the minimum 
inhibitory concentrations (MICs) of polymyxins come from the SENTRY 
Antimicrobial Surveillance Program (2006-2009), summarized in Table 1.1. 
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Table 1.1: In vitro susceptibility of Polymyxin B in Clinical Isolates of Gram-Negative Bacteria from 
SENTRY Antimicrobial Surveillance Program (2006-2009) (Gales, Jones, & Sader, 2011) 
Polymyxins MIC method Species (no.of isolates) MIC50 
(µg/ml) 
 
MIC90 
(µg/ml) 
Susceptible (%) 
Polymyxin B 
 
Broth microdilution Acinetobacter spp. (4686) 
E coli (17,035) 
Klebsiella spp. (9774) 
P. aeruginosa (9130) 
≤0.5 
≤0.5 
≤0.5 
1.0 
≤0.5 
≤0.5 
≤0.5 
1.0 
99.2 
99.6 
98.6 
99.8 
 
Colistin Broth microdilution Acinetobacter spp. (4686) 
E coli (17,035) 
Klebsiella spp. (9774) 
P. aeruginosa (9130) 
≤0.5 
≤0.5 
≤0.5 
1.0 
1.0 
≤0.5 
≤0.5 
1.0 
98.6 
99.8 
98.5 
99.6 
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As per Clinical and Laboratory Standard Institute (CLSI) guidelines, the 
susceptibility breakpoints for polymyxin B and colistin tested for P. aeruginosa, 
Acinetobacter spp. and Enterobacteriaceae spp. are identical; MIC of ≤ 2 µg/ml is 
regarded as susceptible. However, the susceptibility guidelines reported by the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) are ≤ 4 
µg/ml for Pseudomonas spp. and ≤ 2 µg/ml for Acinetobacter spp.as well as 
Enterobacteriaceae (Bergen et al., 2012). 
 
 
1.1.6 Pharmacodynamics of Polymyxins 
Both polymyxin B and colistin are reported to display similar 
pharmacodynamic characteristics. Tam et al. examined the effect of dose 
fractionation on the bactericidal activity of polymyxin B against Pseudomonas 
aeruginosa using an in vitro hollow fiber infection model. The wild-type and MDR 
strain of P. aeruginosa Polymyxin B were exposed to polymyxin B using three 
different dosing regimens (8, 12 and 24-hourly administration of the same daily 
dose) to simulate the steady-state polymyxin B pharmacokinetics in patients. 
This in vitro model was designed to expose the fluctuating concentrations of 
polymyxin B to the bacterial population over time with linear elimination and 
repeated dosing for 4 days. With all three dosing regimens against both strains, a 
rapid bacterial killing was observed in a concentration-dependent manner 
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followed by the regrowth (as early as 6 hours after first exposure). It was 
concluded that the most important factor was the total daily dose whereas dose 
fractionation or alteration in dosing frequency had no significant impact on the 
overall bactericidal activity of polymyxin B. They found that the in vitro 
bactericidal activity was well correlated with the ratio of area under the 
concentration-time curve to the minimum inhibitory concentration (AUC/MIC), 
which was the best-fitted pharmacokinetic/pharmacodynamic index for polymyxin 
B (Tam et al., 2005). Polymyxin B was also reported to exhibit similar 
pharmacodynamics with initial rapid bactericidal activity in vitro against A. 
baumannii and K. pneumoniae followed by a regrowth phase (Abdul Rahim et al., 
2015; Tran et al., 2016).  
 
Colistin exhibits very similar pharmacodynamics to that of polymyxin B, 
with similar initial rapid bactericidal activity followed by a quick regrowth phase 
(as early as 2 h after first drug exposure). Several in vitro time-kill studies 
reported concentration-dependent bacterial killing by colistin against A. 
baumannii and K. pneumoniae and P. aeruginosa (Bergen et al., 2010; Owen, Li, 
Nation, & Spelman, 2007; Poudyal et al., 2008). Another study investigated the 
pharmacodynamics of colistin in the mice thigh and lung infection models 
directed against several strains of Gram-negative bacteria. Similar to polymyxin 
B, it was found that the pharmacokinetic/ pharmacodynamic index that best fitted 
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the efficacy of colistin was fAUC/MIC ratio (Dudhani, Turnidge, Coulthard, et al., 
2010; Dudhani, Turnidge, Nation, & Li, 2010). Collectively, these findings suggest 
that the total daily exposure is related to the bactericidal activity of polymyxins.  
 
 
1.1.7 Dosage Guidelines 
The currently used dosing guidelines for polymyxins are based on total 
body weight and the renal function of patients. These dosing recommendations 
for polymyxin B are empirical and may need to be re-evaluated. The current 
dosing recommendations for the polymyxins are summarized in Table 1.2. 
 
 
 
 
 
 
 
 
 
 13 
 
Table 1.2: Current Dosing Guidelines for Intravenous Polymyxin B and 
Colistimethate Sodium (Landman, Georgescu, Martin, & Quale, 2008; Yuan 
& Tam, 2008) 
A. Polymyxin B dosing for adults and children older than two years 
 
Renal function Dosing recommendation 
Normal renal function 
(CrCl > 80 ml/min) 
1.5 – 2.5 mg/kg/day (15,000 – 25,000 IU/kg) in two 
divided doses 
Mild renal insufficiency 
(CrCl 30 - 80 ml/min) 
2.5 mg/kg of loading dose on day 1; then 1 -1.5 
mg/kg/day  
Moderate renal insufficiency 
(CrCl < 30 ml/min) 
 2.5 mg/kg of loading dose on day 1; then 1 -1.5 
mg/kg/day every 2-3 days 
 
Anuria 2.5 mg/kg of loading dose on day 1; then 
11.5 mg/kg/day every 5-7 days                               
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B. Colistimethate Sodium (Colomycin) Dosing for Adults 
 
Renal function Dosing recommendation 
Normal renal function 
(CrCl > 50 ml/min) 
4 - 6 mg/kg/day colistimethate in three divided 
doses (50,000-75,000 IU for patients ≤ 60 kg); 80 
– 160 mg colistimethate every 8 h (1 – 2 million 
IU for patients > 60 kg) 
Mild renal insufficiency 
(CrCl 20 - 50 ml/min) 
80 - 160 mg/kg/day (1 -2 million IU) colistimethate 
every 8 h  
Moderate renal insufficiency 
(CrCl 10 - 20 ml/min) 
 80 mg/kg/day (1 million IU) colistimethate every  
12 - 8 h  
Severe renal insufficiency 
(CrCl < 10 ml/min) 
80 mg/kg/day (1 million IU) colistimethate every 
18 - 24 h 
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1.1.8  Nephrotoxicity of polymyxins: Prevalence and Risk Factors 
Dose-dependent nephrotoxicity is the most prevalent adverse effect which 
hinders the clinical use of polymyxins. With the acceptance of RIFLE (risk, injury, 
failure, loss and end-stage kidney disease) criteria in 2004, a consensus 
definition of nephrotoxicity has been developed (Wertheim et al., 2013). 
Thereafter, some noteworthy attempts have been made in assessing the rate of 
nephrotoxicity associated with polymyxins using this criterion. A recent 
retrospective study reported the nephrotoxicity rates evaluated in 173 critically ill 
patients receiving intravenous colistin and polymyxin B were 60.4% and 41.8%, 
respectively (Akajagbor et al., 2013). Another study from our lab reported 45.8% 
as the overall prevalence rate of nephrotoxicity with parenteral use polymyxin B 
(Dubrovskaya et al., 2015). Similarly, in recent studies conducted utilizing the 
RIFLE criteria, the prevalence of colistimethate-associated nephrotoxicity was 
estimated to be approximately 45% (Hartzell et al., 2009; Pogue et al., 2011). 
Furthermore, among the various independent risk factors evaluated, the total 
daily dose of polymyxins (both, polymyxin B and colistimethate) was identified as 
an independent risk factor correlated with the onset of nephrotoxicity (Phe et al., 
2014).  
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 A careful review of recent literature on the polymyxin nephrotoxicity 
revealed a higher rate of nephrotoxicity associated with colistin/ colistimethate 
sodium (55.3%) as compared to polymyxin B (21.1%) (Phe et al., 2014). Owing 
to the lower rate of nephrotoxicity but similar antibacterial activity, polymyxin B 
was our preferred therapeutic agent against MDR infections. Therefore, after a 
thorough, extensive and careful appraisal of polymyxins, our later investigations 
into the intricacies of pharmacokinetics, toxicodynamics and mechanism(s) of 
intrarenal uptake were solely carried out using polymyxin B. To begin with, we 
focused on identifying the existing knowledge gap in the current understanding of 
polymyxin B pharmacokinetics and toxicity profile in our literature review. 
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1.2 Knowledge Gap: Current Understanding of Pharmacokinetics, 
Biodistribution, Transport Mechanisms and Toxicodynamics of 
Polymyxin B 
      There is a paucity of published reports correlating pharmacokinetics and 
toxicodynamic profiles of polymyxin B. Moreover, we lack a deep understanding 
of the in vivo biodistribution, disposition, cellular transport, and mechanism(s) of 
intrarenal uptake of polymyxin B. This knowledge gap hinders the design of 
optimal dosing strategies. Nephrotoxicity concerns are escalating with the 
ongoing usage of current polymyxin B dosing approaches. These dosing 
schemes are commonly associated with a high incidence of nephrotoxicity. 
Previously, few studies have provided evidence suggesting that polymyxin B is 
non-renally eliminated (Abdelraouf, He, Ledesma, Hu, & Tam, 2012; Zavascki et 
al., 2008). A follow-up pharmacokinetic study in the same rat model, however, 
illustrated prolonged residence of polymyxin B in the kidneys. These results 
revealed that polymyxin B persisted in the rat kidneys long after the serum 
concentration was below the lower limit of quantification (Abdelraouf, He, 
Ledesma, Hu, & Tam, 2012). This prolonged persistence in the kidneys might 
contribute to its nephrotoxic potentials. 
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      Most clinical reports on polymyxin B pharmacokinetics are derived from 
patient populations are focused mainly on the serum concentration-time profile. 
However, the serum concentration alone may not provide comprehensive 
insights on the overall drug pharmacokinetics, particularly if the drug exhibits an 
atypical biodistribution pattern. It has been previously reported that organ 
distribution of polymyxin B was non-uniform, with greater accumulation in 
kidneys, liver and muscle tissues (Kunin, 1970). Similarly, Jacobson et al. 
investigated the in vivo distribution and binding of tritiated polymyxin B in a 
mouse model and results were in agreement with the previous report. The 
distribution pattern of polymyxin B was non-uniform, and the drug was rapidly 
accumulated in the kidney (Jacobson, Koch, Kuntzman, & Burchall, 1972).  
 
      Dose-limiting nephrotoxicity remains at the crux of the unresolved 
problems associated with clinical use of polymyxin B. A previous study from our 
lab provided circumstantial evidence that the renal tissue concentration of 
polymyxin B was associated with the onset and severity of drug-induced 
nephrotoxicity (Abdelraouf, Braggs, et al., 2012). The same total daily dose of 
polymyxin B administered subcutaneously every 6 h was associated with an 
earlier nephrotoxicity onset as compared to the once daily dosing. Interestingly, 
these findings insinuated that renal tissue concentration of polymyxin B could be 
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considered as a major determinant while investigating a potential correlation 
between polymyxin B daily dose and the onset of nephrotoxicity. Therefore, it is 
crucial to evaluate in-depth renal exposure of polymyxin B in addition to its serum 
pharmacokinetic profile.                 
 
          Until now the underlying mechanism(s) of polymyxin B-induced 
nephrotoxicity and intrarenal uptake has not been well established. Several 
aspects of preferential intrarenal accumulation of polymyxin B still remain 
unanswered. The mechanistic factors driving the uptake of polymyxin B into renal 
cells remain unexplored. Despite a previous report investigating the involvement 
of transporters in renal uptake of colistin using isolated perfused rat kidney, there 
is lack of published literature available on the renal uptake of polymyxin B. Ma et 
al, proposed that renal reabsorption of colistin could potentially be mediated by 
organic cation transporter (OCT) and peptide transporter (PEPT-2) inhibited by 
tetraethylammonium and glycine-glycine, respectively (Ma et al., 2009).  
However, no direct evidence was further provided to support this hypothesis in 
an cellular/animal model.  
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      To date, we have sparse information on the impact of renal accumulation 
of polymyxin B and its contribution towards drug-induced nephrotoxicity. 
Additionally, few studies have reported that daily dosing is one of the primary 
independent risk factors associated with polymyxin B-induced nephrotoxicity 
(Dubrovskaya et al., 2015; Mendes, Cordeiro, & Burdmann, 2009; Phe et al., 
2014). A recent study reported that high concentration and prolonged residence 
of polymyxin B triggered events causing cell death. Several notable 
morphological changes in mitochondria, including loss of membrane potential, 
were observed, leading to cellular apoptosis in the rat (NRK-2E) and human (HK-
2) kidney proximal tubular cells lines (Azad et al., 2013).  However, these reports 
do not provide a concrete mechanistic framework correlating renal drug exposure 
and the onset of polymyxin B nephrotoxicity. Therefore, there remains a critical 
need to elucidate the precise mechanism of polymyxin B-induced nephrotoxicity 
to ensure safe clinical use that will attenuate toxicity concerns. It is pivotal to 
delineate the mechanism of intrarenal uptake of polymyxin B in order to identify 
the pharmacological target responsible for intracellular uptake. The outcome of 
this mechanistic study can be further translated to designing novel polymyxin B 
analogues with little or no affinity towards the identified pharmacological target. 
This would further minimize the intrarenal accumulation and diminish the 
incidence of nephrotoxicity.  
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1.3   Research Objectives 
The long-term goal of our research is to design safe and effective 
treatment strategies against infections caused by MDR Gram-negative bacteria. 
Over the past few decades, polymyxin B has re-emerged in clinical settings as a 
last treatment resort against challenging Gram-negative infections,. It is crucial to 
ensure its safe clinical use until new and effective therapeutic options are 
available.  
Our central hypothesis is that polymyxin B is non-uniformly distributed in 
vivo and accumulates predominantly in the kidneys. We hypothesize that 
preferential accumulation of polymyxin B in renal tissues is correlated to the 
onset of dose-dependent nephrotoxicity. Therefore, the objectives of the 
proposed research are first, to provide additional insights into the overall 
distribution and disposition characteristics of polymyxin B using an animal model. 
Secondly, we aim to establish a correlation between renal drug exposure and the 
onset of nephrotoxicity, in conjunction with delineating the role of underlying 
uptake transport system in the renal accumulation of polymyxin B.  
        The outcome of this research could be used in identifying the 
pharmacological target and designing future interventions to alleviate polymyxin 
B-induced nephrotoxicity. It is anticipated that the results of this investigation will 
elucidate the details of polymyxin B pharmacokinetics. This would guide future 
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studies to facilitate the optimization of appropriate dosing strategies, which 
maximize efficacy and minimize the incidence of nephrotoxicity. In the long run, 
the optimization of polymyxin B dosing strategies based on the sound knowledge 
of drug pharmacokinetics/ toxicodynamics to ensure greater safety and efficacy 
in clinical settings is warranted. Figure 1.3 represents the advantages of the 
innovative approaches to dosing polymyxin B as compared to the currently used 
paradigm. 
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Figure 1.3: Advantages of Proposed Approach over Conventional Approach 
 
 
 
 
 
Incidence of nephrotoxicity 
 
 
 
Incidence of nephrotoxicity
Limited knowledge of 
intrarenal accumulation 
Conventional approach 
Clinical use results in 
Polymyxin B 
Proposed approach 
Understanding renal 
pharmacokinetics and 
drug disposition 
Intervention circumventing 
intrarenal accumulation 
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1.4 Research Design 
The proposed research design was implemented as depicted in the Figure 1.4. 
Figure 1.4: Flowchart Depicting the Implementation of Research Design 
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1.5  Research Plan  
 The overall research plan is designed to be conducted using three specific 
aims, which are intended to be performed sequentially. The step-wise execution 
of these aims will provide insights into the intricacies of polymyxin B 
pharmacokinetics by explaining the biodistribution, disposition, and cellular 
transport mechanism(s) within the kidneys. 
 
 Specific Aim 1: To investigate the organ biodistribution and 
disposition of polymyxin B using a rat model. 
Working hypothesis: Commercially available polymyxin B is a 
mixture of closely related structural analogs (Orwa et al., 2001). 
Preliminary studies from our lab have demonstrated that the in vitro 
potencies of the different polymyxin B components were comparable 
(Tam et al., 2005). Therefore, we hypothesized those various 
components of polymyxin B exhibit similar pharmacokinetic 
characteristics. Clinically, nephrotoxicity is the most prevalent dose-
limiting adverse effect of polymyxin B (Falagas, Kasiakou, Kofteridis, 
Roditakis, & Samonis, 2006; Mendes, Cordeiro, & Burdmann, 2009). 
It has been previously reported that organ distribution of polymyxin B 
was non-uniform with greater accumulation in kidneys, liver and 
muscle tissues (Kunin, 1970). Therefore, we hypothesize that 
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polymyxin B exhibits heterogeneous distribution and preferentially 
accumulates in the kidneys, which contribute to its nephrotoxic 
potentials. 
 
 Specific Aim 2: To investigate the intrarenal distribution of 
polymyxin B in a rat model. 
Working hypothesis: In a previous study, polymyxin B was 
observed to be significantly accumulated in the renal proximal tubular 
cells in a mouse model (Yun, Azad, Nowell, et al., 2015). Our lab has 
demonstrated that polymyxin B-induced renal injuries were mainly 
confined to the proximal tubules (Abdelraouf, Braggs, et al., 2012). 
Therefore, based on these relevant facts we hypothesize that 
proximal tubules are the primary renal cell type with the highest 
accumulation of polymyxin B. 
 
 Specific Aim 3: To elucidate the mechanism(s) that leads to 
intracellular accumulation of polymyxin B within the kidneys 
Working hypothesis: Several studies have earlier reported 
polymyxin B daily dose as one of the primary independent risk factors 
closely associated with its nephrotoxicity (Dubrovskaya et al., 2015; 
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Mendes et al., 2009). Moreover, megalin, a renal endocytic receptor 
playing a critical role in the renal uptake of endogenous compounds 
and xenobiotics, is reported to have a high binding affinity for 
polybasic drugs such as polymyxin B (Moestrup et al., 1995). 
Therefore, we hypothesized that the onset of polymyxin B 
nephrotoxicity was dose dependent: the higher the daily dose, the 
greater the renal drug exposure. Moreover, we hypothesized that the 
intrarenal uptake of polymyxin was mediated by megalin. 
 
1.6 Intrarenal accumulation of Polymyxin B: The Role of Megalin 
Some recent reports have demonstrated that polybasic drugs such as 
polymyxin B, colistin, gentamicin and amikacin have a high binding affinity 
towards megalin, a renal endocytic receptor. It has been speculated that the 
binding of these drugs to megalin leads to their internalization within the kidneys 
as depicted in Figure 1.5   (Dagil, O'Shea, Nykjaer, Bonvin, & Kragelund, 2013; 
Moestrup et al., 1995; Schmitz et al., 2002). Megalin is one of the members of 
the low-density lipoprotein protein-2 (LRP-2) receptor gene family, with a 
molecular weight of approximately 600 kDa (Christensen & Nielsen, 2007; 
Marzolo & Farfan, 2011) as represented in Figure 1.5.  
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Figure 1.5: Schematic Representation of Megalin Localization in Renal 
Proximal Tubular Epithelium (Christensen, Wagner, & Kaissling, 2012; 
Weyer et al., 2013) 
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Megalin is predominantly expressed in the renal proximal tubular 
epithelium, labyrinth membrane of the inner ear and retinal epithelium (Lundgren 
et al., 1997). It is reported to function as an endocytic receptor and is responsible 
for the internalization/uptake of a large variety of endogenous molecules as well 
as xenobiotics (De, Kuwahara, & Saito, 2014). Several endogenous molecules 
such as vitamin D, calcium, lipoprotein lipases, plasminogen activator inhibitor 
type-1 complex and receptor-associated protein (RAP) are known ligands of 
megalin (Ternes & Rowling, 2013; Zheng, Marino, Zhao, & McCluskey, 1998). 
Based on these relevant literature findings, we hypothesized that polymyxin B 
renal uptake could be mediated through megalin. 
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CHAPTER 2 
GENERAL METHODOLOGY AND EXPERIMENTATION 
 
2.1  Polymyxin B Assay 
2.1.1 Ultra Performance Liquid Chromatography-Tandem Mass 
Spectrometry Assay (UPLC-MS/MS) 
 A validated UPLC-MS/MS method for simultaneous detection as well as 
quantification of major components of polymyxin B was developed. The UPLC 
conditions were: system, Waters AcquityTM; column, Acquity UPLC BEH C18 
column (50 mm X 2.1 mm internal diameter, 1.7 µm, Waters, Milford, MA, USA); 
mobile phase A, 0.1% formic acid; mobile phase B, 100% acetonitrile; gradient, 
0-0.5 min, 5% B, 3.2-4.2 min, 15% B, 4.2-4.6 min, 20% B, 4.6-5 min, 80% B, 5-7 
min, 5% B; flow rate, 0.5 ml/min; column temperature, 60 ºC; and injection 
volume, 10 µl. Carbutamide (5 µg/ml) was used as an internal standard.  
 
An API 3200 Qtrap triple quadrupole mass spectrometer (Applied 
Biosystem/MDS SCIEX, Foster City, CA, USA) was used to determine polymyxin 
B concentration in samples by Multiple Reaction Monitoring method (MRM) in the 
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positive ion mode with the transition of m/z 402  m/z 101 for polymyxin B1, m/z 
397  m/z 101 for polymyxin B2, m/z 397  m/z 101 for polymyxin B3, m/z 402 
 m/z 101 for isoleucine polymyxin B1 and m/z 272  m/z 74 for carbutamide. 
The main instrument parameters for mass spectrometer were set as follows: ion 
spray voltage, 5.5 kV; ion source temperature, 650 ºC; gas1, 40 psi; gas2, 40 psi; 
curtain gas, 20 psi. The compound-dependent parameters for polymyxin B 
components (analyte) and carbutamide (internal standard) are represented in 
Table 2.1. The quantification was carried out using software analyst 1.5.2. 
 
The concentrations of various polymyxin B components were quantified by 
constructing a calibration curve using at least eight concentrations of reference 
standards (with known purity of content) (EvoPure®, Bellingham, WA), in different 
matrices. The standard stock solution of polymyxin B1, B2, B3, and Ile-B1 were 
prepared by dissolving a known amount of the reference standards in LCMS 
grade water. The working solutions were obtained by serial dilution of the 
prepared mixture stock solution in 0.1% formic acid to achieve the final 
concentration range of 0.00625 - 32 µl/ml. To establish a calibration curve, blank 
serum (100 µl) was spiked with 40 µl of the above working solutions of the 
standard mixture and 10 µl of the internal standard (carbutamide) solution. To 
precipitate proteins, 5% trichloroacetic acid (150 µl) was added to the mixture, to 
yield a final concentration range of 0.025 - 12.8 µl/ml.
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Table 2.1: Compound-Dependent Parameters for Simultaneous Estimation of Polymyxin B 
Components and Carbutamide using UPLC-MS/MS  
 
Compound MRM Transitions 
[(Q1  Q3) Da] 
Time 
(msec) 
Declustering 
Potential 
(volts) 
Entrance 
Potential 
(volts) 
Collision  
Energy  
(volts) 
Collision Cell  
Exit Potential 
(volts) 
Polymyxin B1 m/z 402  m/z 101 100 34   10               32                 21.39 
Polymyxin B2 m/z 397  m/z 101 100   39  10              27       21.26 
Polymyxin B3 m/z 397  m/z 101 100   39  10              27       21.26 
Isoleucine- 
Polymyxin B1 
m/z 402  m/z 101 100    34  10              32                       21.39 
Carbutamide m/z 272  m/z 74 100    47  10             20       17.76 
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 The linearity of calibration curves for each component was determined by 
the best fit of peak area ratios (analyte area/ internal standard area) versus 
concentration and fitted using a linear regression (1/x2 weighing) method. The 
slope, intercept and correlation coefficient of the linear regression equation for 
each polymyxin B component in various matrices were derived. The lower limit of 
quantification (LLOQ) was determined based on a signal-to-noise ratio 10:1. The 
assay was validated based on accuracy, precision, and inter- and intra-day 
variability, which were well within 15% of the coefficient of variation (CV) and did 
not exceed 20% of the CV for the LLOQ. Figure 2.1 represents a typical UPLC 
chromatogram of spiked major polymyxin B purified standards in rat serum. 
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Figure 2.1: Typical UPLC-MS/MS chromatogram of Major Polymyxin B 
Components and Carbutamide (Internal Standard) in Rat Serum 
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2.1.2  UPLC-MS/MS Assay of Polymyxin B in Rat Serum/Tissue 
Homogenate 
 The UPLC/MS/MS method was modified to determine the concentrations 
of polymyxin B in rat serum, brain, heart, lungs, liver, spleen, kidneys, and 
skeletal muscle tissues (He, Gao, Hu, Chow, & Tam, 2013). The tissue samples 
were homogenized in deionized water (1:2). Briefly, 100 µl of serum or tissue 
homogenate samples were spiked with 10 µl of an internal standard 
(carbutamide 5 µg/ml) and then extracted with 150 µl of 5% trichloroacetic acid. 
The samples were vortexed for 1 min, followed by centrifugation at 18,000 x g for 
20 min at 4ºC as previously described. The supernatant was transferred to a new 
tube and evaporated to dryness under a stream of ambient air. The residue was 
then reconstituted with 100 µl of a mixture of acetonitrile and 0.1% formic acid 
(1:1 v/v). The samples were again centrifuged at 18,000  g for 20 min at 4°C, 
and 10 µl of the supernatant was injected into the UPLC-MS/MS system for 
quantitative analysis.  
 
 The calibration curves of major components of polymyxin B [polymyxin B1 
(PMB1), polymyxin B2 (PMB2), polymyxin B3 (PMB3) and isoleucine polymyxin 
B1 (Ile-PMB1)] in 0.1% formic acid, rat serum, brain, heart, lungs, liver, spleen, 
kidneys and skeletal muscle tissues are represented in Figures 2.2 - 2.10, 
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respectively. The linearity of calibration curves for each component was 
determined by the best fit of peak area ratios (analyte area/ internal standard 
area) versus concentration and fitted using a linear regression (1/x2 weighing) 
method. The linear concentration ranges for PMB1 in 0.1% formic acid, rat 
serum, brain, heart, lungs, liver, spleen, kidneys and muscle tissue homogenate 
were 0.00625- 32 µg/ml, 0.1-12.8 µg/ml, 0.05-12.8 µg/ml, 0.05-12.8 µg/ml, 0.05-
12.8 µg/ml, 0.0125-12.8 µg/ml, 0.05-12.8 µg/ml, 0.05-12.8 µg/ml, and 0.1-6.4 
µg/ml, respectively. The linear regression coefficients were ≥ 0.99 in all the 
calibration curves.  
 
 The assay was validated based on precision, inter and intraday variability 
within 15% of the coefficient of variation and accuracy within 85% -115% for 
lower limit of quantification (LLOQ). With regards to the matrix effect and 
recovery in the serum matrix, the assay method was previously validated in lab 
(He et al., 2013). The matrix effect and recovery in various other rat tissue 
homogenate (brain, heart, lungs, liver, spleen, kidneys and skeletal muscle 
tissues) were estimated by partial validation using 1-2 concentration from their 
linear range. The mean matrix effect and extraction recovery in brain, heart, 
lungs, liver, spleen, kidneys and skeletal muscle tissues homogenate were 
roughly within 90 % - 115% and 89% - 119% range. 
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Figure 2.2: PMB1 Calibration Curve in 0.1% Formic Acid 
Y = 2.3786 x - 0.2275 (r2 = 0.9981) 
 
Figure 2.3: PMB1 Calibration Curve in Rat Serum 
Y = 0.2507 x + 0.0035 (r2 = 0.9963) 
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Figure 2.4: PMB1 Calibration Curve in Brain Tissue Homogenate  
Y = 0.1036 x + 0.0254 (r2 = 0.9935) 
   
Figure 2.5: PMB1 Calibration Curve in Heart Tissue Homogenate  
Y = 0.0963 x + 0.0042 (r2 = 0.9989) 
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Figure 2.6: PMB1 Calibration Curve in Lung Tissue Homogenate  
Y = 0.1077 x - 0.003 (r2 = 0.9945) 
 
Figure 2.7: PMB1 Calibration Curve in Liver Tissue Homogenate  
Y = 0.0453 x + 0.0135 (r2 = 0.9864) 
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Figure 2.8: PMB1 Calibration Curve in Spleen Tissue Homogenate  
Y = 1.93 x + 0.2865 (r2 = 0.9982) 
 
 
 
 
 
 
 
 
Figure 2.9: PMB1 Calibration Curve in Kidney Tissue Homogenate 
Y = 0.099 x + 0.0011 (r2 = 0.9924) 
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Figure 2.10: PMB1 Calibration Curve in Muscle Tissue Homogenate  
Y = 0.075 x + 0.005 (r2 = 0.9979) 
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mixture was spiked with 40 µl of the above working solutions of the standard 
mixture and 20 µl of the internal standard (carbutamide, 5 µg/ml) solution. To 
precipitate proteins, 5% trichloroacetic acid (640 µl) was added to the mixture, 
vortexed for 1 min and then centrifuged at 18,000 x g for 20 min at 4ºC as 
previously described. The supernatant was transferred to a new tube and loaded 
onto Oasis HLB solid-phase extraction (SPE) cartridges (30 mg, 1ml, Waters, 
Milford, MA). The SPE cartridges were preconditioned with 1ml methanol 
followed by 2 x 1ml de-ionized water on a vacuum suction manifold (Supelco, 
Bellefonte, PA). Salts and other impurities were removed by washing with 1ml of 
water. Polymyxin B was eluted with 2 x 1ml of 0.1% formic acid and acetonitrile 
(1:1 v/v) mixture the eluent was evaporated to dryness under a stream of 
ambient air. The residue was then reconstituted with 100 µl of a mixture of 0.1% 
formic acid and acetonitrile (1:1 v/v). The 10 µl of the resultant solution was then 
injected to UPLC-MS/MS. Figure 2.11 represents a typical UPLC chromatogram 
of spiked major polymyxin B purified standards in rat urine samples. The linear 
concentration ranges for PMB1 in urine samples was 0.025 – 12.8 µg/ml. The 
linear regression coefficients were ≥ 0.99 in all the calibration curves as shown in 
Figure 2.12.  
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Figure 2.11: Typical UPLC-MS/MS Chromatogram of Major Polymyxin B 
Components and Carbutamide in Rat Urine  
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Figure 2.12: PMB1 Calibration Curve in Rat Urine 
Y = 0.1161 x + 0.0077 (r2 = 0.9954)   
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2.1.4 UPLC-MS/MS Assay of Polymyxin B in Rat Bile 
The UPLC/MS/MS method was modified to determine the concentrations 
of polymyxin B in rat bile. Briefly, 20 µl of bile was first spiked with 50 µl blank 
serum (> 2 times the volume of bile) as an attempt to minimize matrix effect 
caused due to bile components. Then, 10 µl internal standard (carbutamide 5 
µg/ml) added to it followed by 130 µl of 5% trichloroacetic acid to precipitate 
proteins. The samples were vortexed for 1 min, followed by centrifugation at 
18,000 x g for 20 min at 4ºC as previously described. The supernatant was 
transferred to a new tube and loaded onto Oasis HLB solid-phase extraction 
(SPE) cartridges (30 mg, 1ml, Waters, Milford, MA). The SPE cartridges were 
preconditioned with 1ml methanol followed by 2 x 1ml de-ionized water on a 
vacuum suction manifold (Supelco, Bellefonte, PA). Salts and other impurities 
were removed by washing with 1ml of water. Polymyxin B was eluted with 2 x 
1ml of 0.1% formic acid and acetonitrile (1:1 v/v) mixture and the eluent was 
evaporated to dryness under a stream of ambient air. The residue was then 
reconstituted with 100 µl of a mixture of 0.1% formic acid and acetonitrile (1:1 
v/v). The 10 µl of the resultant solution was then injected to UPLC-MS/MS. 
Figure 2.13 represents a typical UPLC chromatogram of spiked major polymyxin 
B purified standards in rat bile samples. The linear concentration ranges for 
PMB1 in bile samples was 0.05 – 12.8 µg/ml. The linear regression coefficients 
were ≥ 0.99 in all the calibration curves as shown in Figure 2.14.  
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Figure 2.13: Typical UPLC-MS/MS Chromatogram of Major Polymyxin B 
Components and Carbutamide in Rat Bile 
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Figure 2.14: PMB1 Calibration Curve in Rat Bile 
Y = 0.0716 x - 0.0096 (r2 = 0.9869) 
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2.2  Microbiological Assay of Polymyxin B in Rat Urine 
A validated microbiological assay method was also modified to determine 
the concentrations of pharmacologically active polymyxin B in the rat urine 
samples, as previously described (He, Figueroa, Lim, Chow, & Tam, 2010). 
Bordetella bronchiseptica ATCC 10580, obtained from American Type Culture 
Collection (Manassas, VA), was used as the reference organism. Bacteria in 
logarithmic-phase growth were incorporated into 30 ml of molten cation-adjusted 
Muller Hilton II Agar at 50 ºC to achieve a final concentration of approximately 
1000,000 CFU/ml. The agar was allowed to solidify in 150-mm medium plates. A 
size 3 cork bore was used to puncture nine wells in the agar plate. Five 
polymyxin B standards (4, 8, 16, 32 and 64 µl), blank and urine sample from 
three rat (40 µl each) were placed on each plate. The plates were prepared in 
duplicates and were then incubated at 35 ºC for 24 hours. Further, the elimination 
of polymyxin B in urine was estimated by plotting the calibration curves between 
inhibition zone diameters (mm) versus the logarithmic standard polymyxin B drug 
concentrations in urine from each plate. The assay was previously validated 
based on accuracy, precision, inter and intraday variability (He et al., 2013). The 
LLOQ was determined to be 2 µg/ml.  
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CHAPTER 3 
CHARACTERIZATION OF POLYMYXIN B BIODISTRIBUTION 
AND DISPOSITION 
 
 
3.1 Materials and Method 
3.1.1 Antimicrobial Agent 
 Polymyxin B (USP) was purchased from Sigma-Aldrich (St. Louis, MO) 
and X-GEN Pharmaceuticals, Inc. (Northport, NY).  Prior to each animal 
experiment, polymyxin B (USP) was reconstituted and diluted to the desired 
concentrations with normal saline. The reconstituted drug solutions were stored 
at -80ºC until analysis. 
 
3.1.2 Animals 
Female Sprague-Dawley rats (225-250g) (Harlan, Indianapolis, IN, USA) 
were used. The rats received food and water ad libitum. In selected experiments, 
jugular veins of selected animals were cannulated to facilitate intravenous drug 
administration. The rats were maintained in a 12hr dark/light cycle and in a 
temperature-and-humidity-controlled environment. All animals were cared for in 
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accordance with the highest humane and ethical standards, as approved by 
Institutional Animal Care and Use Committee (IACUC) of the University of 
Houston.  
 
3.1.3  Chemicals and Reagents 
Blank human and rat sera were obtained from Equitech-Bio Inc (Kerrville, 
TX). Carbutamide was purchased from Aldrich (Milwaukee, WI). LC-MS grade 
acetonitrile and water were obtained from Mallinckrodt Baker (Philipsburg, NJ). 
LC-MS grade formic acid was purchased from Fluka Analytical (St. Louis, MO). 
Trichloroacetic acid, phosphate buffer saline with 0.01% were purchased from 
Sigma-Aldrich (St. Louis, MO). Carbutamide was purchased from Aldrich 
(Milwaukee, WI). LC-MS grade acetonitrile and water were obtained from 
Mallinckrodt Baker (Philipsburg, NJ). LC-MS grade formic acid was purchased 
from Fluka Analytical (St. Louis, MO).  
 
3.1.4 Pharmacokinetics of Polymyxin B in Rats  
A total of 17 female Sprague-Dawley rats (225-250g) (Harlan, 
Indianapolis, IN) were used.  The rats were administered a single intravenous 
dose of polymyxin B (3 mg/kg).  Blood samples were obtained at 1, 1.5, 3, 4.5, 6 
and 7.5 h post-dose and allowed to clot on the ice.  Serum samples were 
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obtained by centrifugation (6000x g for 15 minutes at 4ºC) and stored at -80 C 
until drug analysis.  A median of 4 samples (range: 2-8) were obtained at each 
time point, the average concentration of each time point was used for 
pharmacokinetic analysis. 
 
A validated liquid chromatography tandem mass spectrometry (UPLC-
MS/MS) method was used to determine the concentrations of polymyxin B in rat 
and human sera (He et al., 2013). The serum concentrations of each component 
were quantified individually and subsequently reported collectively as the total 
polymyxin B concentration. 
 
3.1.5 Pharmacokinetic Modeling 
The pharmacokinetics of polymyxin B was derived using two different 
approaches.  In the first approach, we used the total polymyxin B concentrations 
in serum. In contrast, the concentration-time profiles of individual polymyxin B 
components were used in the second approach. The dose fractions of the 
individual components were based on their relative abundance in the USP 
mixture (previously estimated to be 0.612, 0.254, 0.056 and 0.077 for polymyxin 
B1, B2, B3 and isoleucine B1, respectively). In both scenarios, a one-
compartment linear model with a zero order input was used to fit the 
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concentration-time profiles using ADAPT 5 (University of Southern California, Los 
Angeles, CA). 
 
3.1.6 Polymyxin B Assay 
  A validated liquid chromatography tandem mass spectrometry 
(UPLC/MS/MS) method was modified to determine the concentrations of 
polymyxin B in rat serum, brain, heart, lungs, liver, spleen, kidneys and skeletal 
muscle tissues (He et al., 2013). Briefly, serum, bile or tissue homogenate was 
spiked with 10 µl of an internal standard (carbutamide 5 µg/ml) and extracted 
with 150 µl of 5% trichloroacetic acid. The samples were vortexed for 1 min, 
followed by centrifugation as previously described (He et al., 2013). The 
supernatant was transferred to a new tube and evaporated to dryness under a 
stream of ambient air. The residue was then reconstituted with 100 µl of a 
mixture of acetonitrile and 0.1% formic acid (1:1 v/v). The samples were again 
centrifuged at 18,000  g for 20 min at 4°C, and 10 µl of the supernatant was 
injected into the UPLC-MS/MS system for quantitative analysis.  
 
The calibration curves in serum/urine/tissue samples were constructed 
using at least eight concentration standards. The linearity of the calibration 
curves was determined by the best fit of peak-area ratios (analyte/internal 
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standard) versus concentrations and fitted using a linear regression (1/x2 
weighing) method. The lower limit of quantification (LLOQ) was determined 
based on the signal to noise ratio of 10:1. The assay was validated based on 
accuracy, precision, inter and intraday variability, which was well within 15% of 
the coefficient of variation (CV) and did not exceed 20% of the CV for the LLOQ 
(He et al., 2013). 
 
A validated microbiological assay method was also modified to determine 
the concentrations of polymyxin B in the rat urine samples, as previously 
described (18). Bordetella bronchiseptica ATCC 10580, obtained from American 
Type Culture Collection (Manassas, VA), was used as the reference organism. 
Bacteria in logarithmic-phase growth were incorporated into 30 ml of molten 
cation-adjusted Muller Hilton II Agar at 50 ºC to achieve a final concentration of 
approximately 1000,000 CFU/ml. The agar was allowed to solidify in 150-mm 
medium plates. A size 3 cork bore was used to puncture nine wells in the agar 
plate. Five polymyxin B standards (4, 8, 16, 32 and 64 µl), blank and urine 
sample from three rats (40 µl each) were placed on each plate. The plates were 
prepared in duplicates and were then incubated at 35 ºC for 24 hours. Further, 
the elimination of polymyxin B in urine was estimated by plotting the calibration 
curves between inhibition zone diameter (mm) versus the logarithmic standard 
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polymyxin B drug concentration in urine from each plate. The assay was 
previously validated based on accuracy, precision, inter and intraday variability; 
LLOQ was determined to be 2 µg/ml. 
 
3.1.7 Biodistribution of Polymyxin B 
 Prior to each experiment, polymyxin B powder was dissolved in sterile 
water for injection and diluted to the desired concentration. The rats were given a 
single intravenous dose of polymyxin B (3 mg/kg) and sacrificed after 3 h (n=3), 6 
h (n=6) and 24 h (n=3), respectively. The harvested tissues were weighed and 
homogenized in deionized water (1:2). The mean tissue/serum drug 
concentration ratios were estimated for each tissue matrix. The groups were 
compared using one-way ANOVA, followed by Tukey’s posthoc test. P-values 
<0.05 were considered significant. 
 
3.1.8 Pre- and Post-Dose Urine Sampling 
The rats (n=3) were housed individually in separate metabolic cages to 
facilitate urine collection. Blank urine was collected from each rat, prior to the 
administration of a single intravenous dose of polymyxin B (3 mg/kg). The 
cumulative urine of each rat was collected daily from day -1 to 2 following drug 
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administration. The urine samples were spun down to remove the particulate 
matter, and volumes were recorded. Subsequently, the urine samples were 
aliquoted and stored at -80 ºC prior to analysis. 
 
3.1.9 Elimination of Polymyxin B in Urine 
Prior to analysis, samples were thawed and loaded into the solid-phase 
extraction cartridges (Oasis HLB 1cc cartridges, 30 µm) preconditioned with 1m 
of methanol and 1 x 2 ml of water. After loading the urine samples, the cartridges 
were washed twice with water followed by eluting solvent (0.1% formic acid in 
water: acetonitrile, 50:50) mixture. Subsequently, the eluent was injected 
UPLC/MS-MS for quantification of polymyxin B in urine samples. To quantify the 
active metabolite of polymyxin B using microbiological assay, the urine sample 
were thawed and concentrated 2X by evaporation to reduce the lower limit of 
detection. The urine samples were then placed in wells of the agar plate 
incorporated with bacteria (Bordetella bronchiseptica ATCC 10580) along with 
the polymyxin B standards in urine as shown in figure 3.3. Subsequently, the 
inhibition zone diameter (mm) of the urine samples were measured for the 
quantification of pharmacologically active form (metabolite if any) of polymyxin B 
eliminated in the urine. 
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3.2  Results 
3.2.1 Pharmacokinetics of Polymyxin B in Rats  
 The overall model fit to the rat data was satisfactory, as shown in Figure 
3.1. In addition, best-fit pharmacokinetic parameters are shown in Table 3.1.  
Strictly speaking, the pharmacokinetic parameters (e.g., clearance and volume of 
distribution) of the individual components were not identical, but most the 
differences were within a 2-fold range.  
 
 The weighted average pharmacokinetic parameters using individual 
components were in reasonably close agreement with those derived directly from 
the total polymyxin B concentrations. The AUC (0-∞) observed for total polymyxin 
B was 10.7 mg.h.L-1, which was comparable to that derived from adding AUC (0-∞) 
of individual polymyxin B components in the mixture (10.9 mg.h.L-1).  A similar 
trend was also observed in the patient samples, as shown in Table 1.   
 
  
 
 
 
 67 
 
Table 3.1: Comparison of the Best-Fit Pharmacokinetic Parameters in Rats 
 
 
 
 
 
 
 
 
 
 
 
NOTE. AUC (0-∞), area under the concentration curve from zero to infinity; CL, clearance; V, volume of distribution; 
Ke, elimination rate constant; T1/2, elimination half-life. 
* Weighted average based on the relative abundance of different polymyxin B component
 
CL  
(L/kg/h) 
V  
(L/kg) 
T1/2 
 (h) 
Ke 
 (h-1) 
AUC(0-∞)  
(mg.h.L-1) 
R2 
Total PMB 0.28 1.00 2.47 0.28 10.71 
 
0.90 
PMB1       0.30 0.95 2.21 0.31 6.17 
 
0.91 
PMB2 0.32 1.16 2.50 0.28 2.37 
 
0.93 
PMB3 0.15 0.75 3.59 0.19 1.16 
 
0.63 
Ile-PMB1 0.19 1.02 3.76 0.18 1.23 
 
0.71 
Weighted 
average* 
0.29 1.00 2.48 0.29  
 
Sum of individual 
components 
    10.93 
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Figure 3.1: Model Fitting of Total Polymyxin B and Individual Components 
 
 
 
 
 
 
 
 
 
 
 
The data points represent the average serum concentrations of each time point; error 
bars depict the standard deviations, and solid lines represent the best-fit lines 
 
 
 
 69 
 
3.2.2 Polymyxin B Assay 
 The linear concentration ranges for polymyxin B in serum, bile, brain, 
heart, lungs, liver, spleen, kidneys and muscle tissue homogenate were 0.1-12.8 
µg/ml, 0.05-12.8 µg/ml, 0.05-12.8 µg/ml, 0.05-12.8 µg/ml, 0.05-12.8 µg/ml, 
0.0125-12.8 µg/ml, 0.05-12.8 µg/ml, 0.05-12.8 µg/ml, and 0.1-6.4 µg/ml, 
respectively. The linear concentration range for polymyxin B in urine samples 
was 0.025-12.8 µg/ml.  The linear regression coefficients were ≥ 0.99 in all the 
calibration curves. For the microbial assay of polymyxin B in urine, the linear 
concentration range was 2-64 µg/ml respectively.  
 
3.2.3 Biodistribution of Polymyxin B 
 Among all the organs evaluated, polymyxin B distribution was the highest 
in the kidneys. The mean renal tissue/serum polymyxin B concentration ratios 
were 7.45 (95 % CI, 4.63-10.27) at 3 h and 19.62 (95 % CI, 5.02-34.22) at 6 h 
post-dose, respectively as shown in Figure 3.2. As shown in Table 3.2, all tissue 
concentrations at 24 h were lower than those observed at 6 h, but the mean 
tissue/serum ratio at 24 h could not be calculated because the polymyxin B 
concentration in the serum was below the limit of detection. The kidney 
concentration at 24 h was roughly 1.4-5.8 times those observed in organs other 
than the brain. Polymyxin B levels in the brain remained consistently lower than 
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that observed in serum. All other organs exhibited a similar distribution profile as 
serum (Figure 3.2).  
 
3.2.4 Elimination of Polymyxin B in Urine 
 We observed that less than 1% of dose of polymyxin B was eliminated in 
the urine in unchanged form whereas less than 5% of the dose of polymyxin B 
was eliminated in pharmacologically active form. 
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Figure 3.2: Tissue/Serum Concentration Ratio of Polymyxin B in Various 
Tissues; (A) 3 h Post-Dose, (B) 6 h Post-Dose  
A. 
 
 
 
B.  
 
 
 
 Vertical error bars represent the 95% confidence intervals 
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Table 3.2: Biodistribution of Polymyxin B in Rat Serum and Tissue Homogenates 
Time (h) 
 
 Polymyxin B concentrations (mean ± SD) 
 
 
Serum 
(µg/ml) 
Kidney 
(µg/g) 
Muscle 
(µg/g) 
Liver (µg/g) 
Heart 
(µg/g) 
Lung 
(µg/g) 
Spleen 
(µg/g) 
Brain 
(µg/g) 
3 1.46 ± 0.38 10.57 ± 1.21 1.31 ± 0.41 1.10 ± 0.29 1.50 ± 0.78 4.93 ± 3.71 0.86 ± 0.43 0.04 ± 0.04 
6 0.69 ± 0.29 11.32 ± 5.06 0.77 ± 0.34 0.82 ± 0.24 0.57 ± 0.18 1.33 ± 0.41 1.11 ± 0.50 0.02 ± 0.02 
24 < LLOQ 0.76 ± 0.41 0.53 ± 0.18 0.13 ± 0.04 0.28 ± 0.06 0.25 ± 0.04 0.50 ± 0.07 0.01 ± 0.02 
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Figure 3.3: Microbiological Assay of Polymyxin B in Rat Urine
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CHAPTER 4 
INTRARENAL DISTRIBUTION OF POLYMYXIN B 
 
4.1 Materials and Method 
4.1.1 Antimicrobial Agent 
 Polymyxin B sulfate (USP) powder was purchased from Sigma-Aldrich (St. 
Louis, MO). Prior to each experiment, the drug was reconstituted and diluted to 
the desired concentrations with normal saline. The reconstituted drug solutions 
were stored at -80ºC until analysis. 
 
4.1.2 Animals 
Female Sprague-Dawley rats (225-250g) (Harlan, Indianapolis, IN, USA) 
were used. The rats received food and water ad libitum. In selected experiments, 
jugular veins of selected animals were cannulated to facilitate intravenous drug 
administration. The rats were maintained in a 12hr dark/light cycle and a 
temperature-and-humidity-controlled environment. All animals were cared for in 
accordance with the highest humane and ethical standards, as approved by 
Institutional Animal Care and Use Committee (IACUC) of the University of 
Houston. 
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4.1.3  Chemicals and Reagents 
Polymyxin B sulfate (USP) powder, trichloroacetic acid, phosphate buffer 
saline with 0.01% Tween 80 (PBST), 4% paraformaldehyde (PFA), 30% sucrose 
solution in phosphate buffer saline (PBS) were purchased from Sigma-Aldrich 
(St. Louis, MO).Normal goat serum, streptavidin DyLight 488 (green) and 649 
(red), fluorogel-II with DAPI (blue) were obtained from Jackson ImmunoResearch 
Laboratories (West Grove, PA). Anti-mouse IgG secondary antibody, avidin-
biotin blocking kits and biotinylated lectins were purchased from Vector 
Laboratories (Burlingame, CA). The natural sources, targeted nephron regions 
and optimal dilutions of various lectins are listed in Table 4.1. 
 
4.1.4  Harvesting and Processing of Rat Kidney 
  The rats (n=3) were given a single intravenous dose of polymyxin B (4 
mg/kg) and sacrificed at 6 h post-dose. The kidneys were perfusion-fixed with 4% 
paraformaldehyde and stored overnight. Subsequently, the kidneys were 
cryoprotected in 30% sucrose solution in PBS and finally cryosectioned at 20 µm 
intervals into thin tissue cross-sections.  
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4.1.5 Identification of Renal Cell Type and Immunostaining for Polymyxin B 
Different anatomical regions of the nephron were identified by staining 
with specific lectin markers. The fresh frozen kidney tissue sections were placed 
in PBST maintained at pH 7.4 for 5-10 min before staining. Briefly, the sections 
were pre-incubated in avidin-biotin blocking solution, followed by incubation with 
biotinylated lectins diluted with PBST to the concentrations specified in Table 4.1, 
each for 30 min at room temperature. After washing 3 times in PBST, the 
sections were incubated for 30 min at room temperature with streptavidin DyLight 
649 (10 µg/ml diluted in PBST). Subsequently, the sections were washed in 
PBST followed by washing 3 times with distilled water. The sections were then 
mounted using the fluorogel-II mounting agent with DAPI. Controls were 
prepared by the same staining procedure, except that the lectins were replaced 
by PBST.  
 
The double immunostaining of renal tissue section was carried out using 
polymyxin B antibody and lectins. The sections were incubated with 5% normal 
goat serum followed by incubation with an avidin-biotin blocking solution for 30 
min at room temperature. Subsequently, the sections were treated with 
polymyxin B antibody (1:20 dilution in 5% normal goat in PBS) for 1 h at 4°C, and 
later incubated with biotinylated mouse anti-polymyxin B antibody (1:150 dilution 
in 5% normal goat serum). After washing 3 times with PBST, the sections were 
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incubated with streptavidin DyLight 488 (10 µg/ml, diluted in PBST) for 30 min 
each at room temperature. Subsequently, staining with a specific lectin marker 
was performed on the same tissue section, as described above. Controls were 
prepared by same staining procedure except primary antibody and lectins were 
replaced by PBST. 
 
4.1.6 Co-localization of Polymyxin B Antibody with Lectin 
 Images were captured using an Olympus IX61 DSU. Several region of 
interest (ROI) were randomly selected from individual overlay/co-localized image 
for each cell type. Selected ROI(s) from each overlay image were further 
analyzed using a computer-assisted software Image J (version 1.47); the 
Mander's overlap coefficient (Rcolo), which signifies the percentage of overlap of 
two signal intensities, was calculated using Just Another Co-localization Plug-in 
(JACoP). The coefficient value above 0.7 was deemed to be a good degree of 
co-localization. 
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4.2  Results  
4.2.1 Identification of Renal Cell Type and Immunostaining for Polymyxin B 
  A gross cross-section of the kidney revealed that the intrarenal 
distribution of polymyxin B was heterogeneous, as shown in Figure 4.1. 
Polymyxin B accumulated mainly in the renal cortex and outer stripe of the outer 
medulla.  
 
 The differential staining pattern was satisfactory with each lectin marker, 
as shown in Figure 4.2. Strong, focal staining of the brush border epithelium of 
proximal tubular cells was seen with Phaseolus vulgaris erythroagglutinin (PHA-
E) lectin. Soybean agglutinin (SBA) lectin predominantly stained the distal 
convoluted tubular cells. The staining pattern of SBA lectin was reasonably 
distinct; cytoplasmic staining of distal cells was observed. For glomeruli, a strong, 
global and diffused staining pattern was seen with Wheat germ agglutinin (WGA) 
lectin.  
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Figure 4.1: Confocal Images of a Kidney Cross-Section 
 
 
Panel A represents a kidney cross-section from control rat whereas panel B 
represents a cross-section from polymyxin B-treated rat. Blue color represents 
counterstaining with nuclear stain (DAPI) whereas green color represents 
staining with anti-polymyxin B antibody.
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Table 4.1: Lectins Used for the Staining of Rat Kidney Cross-Section 
Lectin Source Target 
Final dilution of lectin 
in PBST (µg/ml) 
Phaseolus vulgaris erythroagglutinin 
(PHA-E) 
Red kidney bean 
Proximal convoluted tubules 
(PCT) 
 
10 
 
Glycine max/ Soybean agglutinin 
(SBA) 
Soybean 
Distal convoluted tubules 
(DCT) 
 
20 
 
Wheat germ agglutinin 
(WGA) 
Wheat germ Glomerulus 20 
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Figure 4.2: Lectin Staining Pattern in Cortical Region of a Rat Kidney 
Cross-Section 
 
 
Panel A-C represent the control section; D-F represents the staining with lectins; 
I-K represents multichannel images of lectin stained kidney sections. Blue color 
represents counterstaining with nuclear stain (DAPI) whereas red color 
represents staining with specific lectins targeted toward different regions of the 
nephron.
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4.2.1 Co-localization of Polymyxin B Antibody with Lectin 
 The double staining with polymyxin B antibody and lectins is shown in Figure 4.3. 
Polymyxin B was found to be accumulated primarily in the proximal tubular cells, with 
Mander’s overlap coefficient (Rcolo) of 0.998 for proximal tubular cells, 0.366 for distal 
tubular cells and 0.097 for the glomerulus, respectively as shown in Table 4.2. 
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Figure 4.3: Double Staining with Polymyxin B Antibody and Lectins a Rat Kidney 
Cross-Section 
 
 
Panel A-C represent control section; D-F represents the staining with anti-polymyxin B 
antibody; G-I represent staining with lectin; J-L represents multichannel images of 
double staining with polymyxin B antibody and lectin.  
Green color represents staining with anti-polymyxin B antibody and red color represents 
staining with specific lectin marker, respectively. The green-red co-localized signals 
produced a yellow signal in the overlay images
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Table 4.2: Semi-Quantitative Analysis to Assess Degree of Co-Localization 
in Various Renal Cell Types 
Renal cell type Mander’s overlap 
coefficient (Rcolo) 
Degree of co-localization 
Proximal convoluted tubules 
(PCT) 
0.998 99.8 % 
Distal convoluted tubules 
(DCT) 
0.366 33.6 % 
Glomerulus 0.097 9.7 
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CHAPTER 5 
CORRELATION BETWEEN ONSET OF POLYMYXIN B 
NEPHROTOXICITY, RENAL DRUG EXPOSURE AND ROLE OF 
MEGALIN 
 
5.1 Materials and Method 
5.1.1 Antimicrobial Agent 
 Polymyxin B sulfate (USP) powder was purchased from APP 
Pharmaceuticals, LLC (lot number 6107834) (Schaumburg, IL, USA) and Sigma-
Aldrich (St. Louis, MO, USA). Prior to each experiment, the drug was 
reconstituted and diluted to the desired concentrations with normal saline. The 
reconstituted drug solutions were stored at -80ºC until analysis. 
 
5.1.2 Animals 
Female Sprague-Dawley rats (225-250g) (Harlan, Indianapolis, IN, USA) 
were used. The rats received food and water ad libitum. All animals were cared 
for in accordance with the highest humane and ethical standards, as approved by 
Institutional Animal Care and Use Committee (IACUC) of the University of 
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Houston. Jugular veins of selected animals were cannulated to facilitate 
intravenous drug administration. 
 
5.1.3  Chemicals and Reagents 
  Sodium maleate dibasic salt was obtained from Sigma-Aldrich. LC-MS 
grade acetonitrile and water were obtained from Mallinckrodt Baker (Philipsburg, 
NJ, USA); LC-MS grade formic acid was purchased from Fluka Analytical (St. 
Louis, MO, USA). The enzyme-linked immunosorbent assay (ELISA) kit for low-
density lipoprotein receptor-related protein (Lrp2) / megalin was purchased from 
Cedarlane (Burlington, NC, USA). 
 
5.1.4 Polymyxin B Assay    
  A validated liquid chromatography tandem mass spectrometry 
(UPLC/MS/MS) method was modified to determine the concentrations of 
polymyxin B in rat serum and renal tissues, as previously described 
(Manchandani, Zhou, et al., 2016). The LLOQ was 50 µg/ml for all the major 
components of polymyxin B in serum matrix as well as renal tissue homogenate.  
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5.1.5 Correlation between Onset of Nephrotoxicity and Renal Tissue 
Concentration of Polymyxin B  
Prior to each experiment, polymyxin B for injection (USP) was 
reconstituted with sterile water for injection (USP) and diluted to achieve desired 
concentration. The reconstituted drug solution was stored at -80ºC in aliquots 
and thawed before dosing. Three groups of rats (n=13 each) were administered 
escalating dose levels of polymyxin B (5 mg/kg, 10 mg/kg and 20 mg/kg, 
respectively) once daily subcutaneously for up to 7 days. Blood samples 
(approximately 200 µl) were withdrawn via the tail vein at baseline and on a daily 
basis (pre-dosing when applicable). Blood was allowed to clot on the ice and 
serum was separated by centrifugation at 4,000 g for 10 minutes. Serum 
samples (100 µl) were further assayed for creatinine levels using a clinical 
chemistry analyzer (Piccolo Xpress, Abaxis, Inc., Union City, CA). A significant 
elevation in serum creatinine (≥ 2 baseline level) was set as the endpoint for 
nephrotoxicity. Kaplan-Meier survival analysis and log-rank (Mentel-Cox) test 
were used to compare the onset of nephrotoxicity among various groups. Right 
censoring was used if the nephrotoxicity endpoint was not observed by day 7.  
 
To determine the renal tissue concentration of polymyxin B, three rats 
from each dosing group were randomly selected and sacrificed at 24 h after the 
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first dose; kidneys were harvested and homogenized. The major components of 
polymyxin B (polymyxin B1, polymyxin B2, polymyxin B3 and isoleucine 
polymyxin B1) were quantified in the renal tissue homogenate (as described 
above). The summed concentration of individual components was used to 
estimate the overall renal drug exposure (Manchandani, Dubrovskaya, Gao, & 
Tam, 2016). One-way ANOVA test followed by post hoc Tukey’s test were used 
to compare the mean renal tissue concentrations among the dosing groups and 
p-values <0.05 were considered significant.  
 
5.1.6 Effect of Maleate Administration on Urinary Excretion of Megalin 
The rats (n=3) were housed individually in separate metabolic cages 24 h 
prior to maleate pre-treatment.  A single dose of 400 mg/kg of sodium maleate 
was given intraperitoneally, and cumulative urine was collected daily from day -1 
to 15. The urine samples were spun down to remove the particulate matter, and 
volumes were recorded. Subsequently, the urine samples were aliquoted and 
stored at -80 ºC prior to analysis. The samples were thawed, and urinary Lrp2 / 
megalin was quantitatively measured using a commercially available ELISA kit 
for megalin. For each animal, the daily megalin concentrations were expressed 
as a normalized ratio to its baseline value.  
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5.1.7 Electron Microscopy of Maleate-Treated Kidney Section 
Two rats were administered a single dose of 400 mg/kg of sodium maleate 
intraperitoneally. One animal was sacrificed at 3 h; the other was sacrificed 14 
days after maleate administration to collect the kidneys. The harvested kidneys 
were cut into thin traverse sections and processed for standard electron 
microscopy sample preparation. Briefly, tissue samples from both renal cortical 
and medullary regions were fixed in 2% glutaraldehyde at 4 ºC overnight, 
followed by additional fixation in osmium tetroxide. Tissue was dehydrated and 
embedded in epoxy resin.  Approximately 1µm thick pilot sections were stained 
with toluidine for selecting the areas for further ultrastructural examination. Thin 
sections of these selected areas were cut and were subjected to examination 
under a Joel 300 electron microscope at 80 kV. The kidneys from two naïve rats 
were harvested, processed in a similar fashion and used as controls. 
 
5.1.8 Polymyxin B Pharmacokinetics in Megalin-Shedding Rats 
The rats were divided into two groups (n=13 each), to study the impact of 
sodium maleate pre-treatment on systemic/renal exposure of polymyxin B. 
Animals in both groups were administered a single intravenous dose of 3 mg/kg 
of polymyxin B sulfate (USP). In contrast, the animals in the treatment group 
were given 400 mg/kg of sodium maleate intraperitoneally 3-6 hours prior to 
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polymyxin B administration. Serum samples were obtained at 1.5, 3, 4.5, 6 and 
7.5 h post polymyxin B dosing. In addition, the rats were sacrificed to harvest the 
kidneys at 3, 6 and 24 h (n=3 at each time point) post-dosing. Polymyxin B 
concentrations in serum and renal tissue samples were assayed by the validated 
UPLC-MS/MS method detailed above. The mean concentrations of polymyxin B 
in serum, as well as renal tissue samples at each time point, were used. A 
modified two-compartment model (Figure 5.5) was used to co-fit the serum / 
renal tissue concentration-time profiles using ADAPT 5. Using the best-fit 
parameters, the area under the curve from 0 to infinity was estimated by 
integrating the instantaneous concentrations over time. The AUC (0-∞) renal tissue/ 
AUC (0-∞) serum ratio, was used as an index to quantitatively assess the preferential 
accumulation of polymyxin B in renal tissue. 
 
To further examine if the effect of sodium maleate on the renal 
accumulation of polymyxin B is transient, three additional rats were given 400 
mg/kg of sodium maleate intraperitoneally. After two weeks of pre-treatment, the 
animals were given with a single dose of 3 mg/kg of polymyxin B intravenously. 
The rats were sacrificed at 3 h post dosing; kidneys were harvested and 
homogenized. Polymyxin B concentrations in renal tissue samples were assayed 
by the validated UPLC-MS/MS method. 
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5.1.9 Absolute Quantification of Polymyxin B Components in Renal 
Tissues and Serum  
To further assess whether any component of polymyxin B demonstrated 
greater affinity towards megalin transporter, we performed absolute quantification 
of each component of polymyxin B (PMB1, Ile-PMB1, PMB2, and PMB3) 
individually in serum as well as renal tissues. Fractions of each component were 
firstly compared between control and sodium maleate treatment group in renal 
tissues to ascertain if any one component was exhibited preferential renal uptake 
due to higher affinity towards megalin. Subsequently, unpaired two-tailed 
student’s t-test was used to analyze the significant difference in the mean 
concentrations of the individual components between control and treatment 
group, both in the serum and renal tissues, respectively.  
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5.2 Results 
5.2.1 Correlation between Onset of Nephrotoxicity and Renal Tissue 
Concentration of Polymyxin B  
  All the animals (10 out of 10) that received 20 mg/kg of polymyxin B 
reached the pre-defined endpoint. In contrast, none of the animals given 5 mg/kg 
of polymyxin B reached the endpoint by day 7.  Furthermore, we observed a 
more gradual onset of nephrotoxicity in the 10 mg/kg group as compared to 20 
mg/kg dosing group, as shown in Figure 5.1. More specifically, 80% (8 out of 10) 
of the animals that received 20 mg/kg reached the endpoint within first 48 h of 
treatment. On the contrary, only 10 % (1 out of 10) animals that received 10 
mg/kg reached pre-defined endpoint within first 48 h of treatment (p < 0.001). 
These findings suggested that a higher daily dose of polymyxin B was associated 
with a more rapid onset of nephrotoxicity. 
 
There was also a similar trend observed in the renal tissue concentration 
of polymyxin B among various dosing groups, as shown in Figure 5.2. The renal 
tissue concentrations of polymyxin B observed were 3.6 ± 0.4 µg/g, 9.9 ± 1.5 
µg/g and 21.7 ± 4.8 µg/g of renal tissue in the 5 mg/kg, 10 mg/kg and 20 mg/kg 
dosing groups, respectively (p = 0.0008). These data implied that drug 
concentration observed in renal tissues was correlated to the daily dose given. 
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Figure 5.1: Comparison of Onset of Nephrotoxicity among Different 
Polymyxin B Dosing Groups 
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Figure 5.2: Renal Tissue Concentration at Escalating Dose Levels of 
Polymyxin B 
 
 
Vertical error bars represent the mean standard deviation within a group. The 
post hoc Tukey’s test was used for multiple 2-way comparisons of mean among 
different groups (***P < 0.001; ** P < 0.01). 
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5.2.2 Effect of Maleate Administration on Urinary Excretion of Megalin 
There was a considerable elevation (approximately 20 times the baseline 
measurement) in the level of urinary megalin post maleate treatment. However, 
the urinary megalin levels reverted gradually to baseline approximately after 11 
days of treatment as represented in Figure 5.3. 
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Figure 5.3: Mean Urinary Megalin Profile Post-Maleate Administration 
 
 
 
 
 
 
 
 
 
 
 98 
 
5.2.3 Electron Microscopy of Maleate-Treated Kidney Section 
The electron microscopic images of control and maleate-treated kidneys 
depicted dramatic differences, as shown in Figure 5.4. No significant 
ultrastructural changes were noticed in the ultrathin sections of the control 
kidney. Specifically, the proximal tubules in control sections revealed intact 
microvilli, mitochondria of normal size, shape, and density, and the presence of 
few microvesicles and lysosomes (Figure 5.4 -A). Of note, there were also no 
noticeable changes seen in glomeruli, blood vessels or any other type of renal 
tubules. In contrast, within 3 h, maleate pre-treatment resulted in the appearance 
of morphological and ultrastructural changes in the proximal tubules which 
included multifocal disruption of microvilli, variation in the sizes and shapes of 
mitochondria. The presence of multiple dilated microvesicles and abundantly 
enlarged lysosomes were few other notable changes seen in the ultrathin 
sections of the maleate-treated kidney, as represented in Figure 5.4-B.  
 
Two weeks after maleate administration, the electron microscopic images 
of ultrathin sections of maleate-treated kidney revealed no significant changes as 
compared to the control kidney sections (Figure 5.4-C). This suggested that the 
maleate-induced ultrastructural alterations in proximal renal tubules were not 
long-lasting.  
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Figure 5.4: Electron Microscopic Images of Control and Maleate-Treated 
Ultrathin Kidney Sections 
A. Control – 3h                            B.  Treatment – 3h          C. Treatment – 14 days 
Panel A: No significant changes were noted in control kidney. Specifically, the proximal 
tubular cells displayed intact microvilli (Vil), mitochondria (Mi) of normal sizes, shapes, 
and density.  A few microvesicles/ lysosomes (Ly) are noted. Panel B: Marked changes 
were noted in proximal tubular cells of the experimental animal, including degenerative 
changes of individual tubular cells (lower right), multifocal disruption or loss of microvilli 
(Vil), abundant mitochondria (Mi) of variable sizes and shapes, and multiple dilated 
microvesicles (Mv). There were no significant changes in glomeruli, blood vessels or 
other types of renal tubules. Panel C: Proximal tubular cells are displaying normal 
features including intact microvilli (Vil), normal mitochondria (Mi), and few lysosomes 
(Ly). [Original magnification x 10,000 for all panels]  
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5.2.4   Polymyxin B Pharmacokinetics in Megalin-Shedding Rats 
 We built a two-compartment (serum-renal tissue) pharmacokinetic model 
with slight modification as represented in Figure 5.5. In both groups (with or 
without maleate pre-treatment), the overall model fits to the data were 
satisfactory. The coefficients of determination for serum concentration-time 
profiles were > 0.94 and for renal concentration-time profiles were > 0.87. The 
AUC (0-∞) serum in both groups were comparable; (11.1 mg.h.L-1 versus 10.4 
mg.h.L-1, respectively). In contrast, the AUC (0-∞) renal tissue were considerably 
different (211.9 mg.h.L-1 and 121.0 mg.h.L-1) in control and treatment group, 
respectively, as represented in Figure 5.6. The AUC (0-∞) renal tissue / AUC (0-∞) serum 
ratios were 19.1 in control and 11.6 in the treatment group, respectively. These 
findings suggested that in megalin-shedding rats, the systemic exposure of 
polymyxin B remained unaltered, but the renal exposure was reduced 
considerably after maleate administration. 
 
 After 2 weeks of treatment with maleate, our results showed that renal 
tissue polymyxin B concentrations in the sodium maleate pre-treated rats were 
comparable to those of the control rats (11.08 µg/g vs. 11.45 µg/g, p = 0.61). This 
finding suggested that the effect of sodium maleate on the renal accumulation of 
polymyxin B was also reversible in nature. 
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Figure 5.5: Structure of Serum-Renal Tissue Pharmacokinetic Co-Model  
 
 
 
 
 
 
 
 
Differential equations: 
dCserum / dt = Kpc × Crenal tissue / D – (Kcp + Ke) × Cserum + R 
dCrenal tissue / dt = Kcp × Cserum – Kpc × Crenal tissue / D 
Where, 
        
Cserum and Crenal tissue: Polymyxin B concentrations in serum and renal tissue; 
Kcp: Inter-compartmental transfer rate constant from central to peripheral 
compartment;  
Kpc: Inter-compartmental transfer rate constant from peripheral to central 
compartment; 
Ke: Elimination rate constant; 
D: Polymyxin B distribution ratio between serum and renal tissue. 
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Figure 5.6: Mean Polymyxin B Concentrations in Serum and Renal Tissues 
A. Serum 
 
 
 
 
 
 
 
 
B.   Renal tissues 
 
 
 
 
 
 
 
Solid and open circles indicate mean serum concentrations of polymyxin B in the 
treatment and control group, respectively; solid and open triangles indicate mean 
renal tissue concentrations of polymyxin B for in the treatment and control group, 
respectively. Dotted line is the best-fit line for the renal concentration-time profile 
in the control group whereas the solid line is the best-fit line for renal tissue 
concentration-time profile in the treatment group, respectively. Vertical error bars 
represent the standard deviation at each time point. 
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5.2.5 Absolute Quantification of Polymyxin B Components in Renal 
Tissues and Serum  
 The absolute quantification of individual components of polymyxin B in the 
renal tissues was represented in Table 5.1 (A & B). The results indicated that 
PMB1 was significantly different between control and treatment group at 3 h 
(p=0.003) and 24 h (p=0.005), respectively. However, the renal concentration of 
PMB2 and Ile-PB1 between two group was observed to be significant different 
only at 3 h (p=0.045) and 24 h (p=0.006), respectively. Our results revealed that 
the renal concentration between both the groups did not remain significantly 
different at all the time points (3, 6 and 24 h) throughout the study. Therefore, the 
overall consistent pattern suggesting the preferential uptake of any particular 
polymyxin B components was not observed in both the groups. This indicated 
that all the polymyxin B components possess fairly similar affinity towards 
megalin. We further compared the quantification of polymyxin B components 
obtained from renal tissue with those derived from serum samples as shown in 
Table 5.1 (B). The absolute quantification in serum samples demonstrated a 
similar trend, and the fractions of individual components were in reasonable 
agreement with those obtained from renal tissues. These results indicated that 
uptake process was not specific for any particular component of polymyxin B; 
individual components exhibited comparable affinity towards megalin transporter. 
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Table 5.1: Absolute Quantification of Polymyxin B Components in Renal 
Tissues, (A) Control and (B) Treatment Group 
A. Control group 
 
 
 
B. Sodium maleate treatment group 
 
 
 
 
 
Time (h) 
Mean serum concentration (µg/ml)                                 
PMB1 Ile-PMB1 PMB2 PMB3 Total PMB 
3 7.13 0.62 2.02 1.62 11.39 
6 8.76 1.13 4.25 2.25 16.39 
24 0.89 ND 0.23 0.18 1.30 
Time (h) 
Mean serum concentration (µg/ml)  
PMB1 Ile-PMB1 PMB2 PMB3 Total PMB 
3 2.16 0.35 1.24 0.96 4.70 
6 4.95 1.01 2.66 1.30 9.92 
24 0.26 ND 0.12 0.09 0.47 
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Table 5.2: Absolute Quantification of Polymyxin B Components in Serum, 
(A) Control and (B) Treatment Group 
A. Control group 
 
 
B. Sodium maleate treatment group 
 
 
Time (h) 
Mean serum concentration (µg/ml)                                                                       
PMB1 Ile-PMB1 PMB2 PMB3 Total PMB 
1.5 1.03 0.15 0.36 0.11 1.64 
3.0       0.96 0.14 0.27 0.09 1.42 
4.5 0.47 0.06 0.16 0.05 0.74 
6.0 0.40 0.05 0.15 0.03 0.62 
7.5 0.24 0.02 0.07 0.02 0.32 
Time (h) 
Mean serum concentration (µg/ml)  
PMB1 Ile-PMB1 PMB2 PMB3 Total PMB 
1.5 1.05 0.15 0.30 0.12 1.62 
3.0       0.65 0.12 0.27 0.08 1.12 
4.5 0.41 0.06 0.15 0.05 0.66 
6.0 0.32 0.05 0.11 0.05 0.53 
7.5 0.18 0.02 0.06 0.01 0.27 
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  5.2.6 Proposed mechanism of Megalin-Mediated Polymyxin B Endocytosis  
 Based on these results we hypothesized that megalin, a renal endocytic 
receptor plays a pivotal role in the renal uptake of polymyxin B through 
microvesicle recycling apparatus. Figure 5.7 demonstrate the diagrammatic 
proposed mechanism of megalin-mediated cellular endocytosis in the proximal 
renal tubules. Sodium maleate inhibits the formation of recycling apparatus which 
is required for the endocytosis of polymyxin B. Consequently, this leads to the 
inhibition of polymyxin B uptake in the proximal renal tubules.  
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Figure 5.7: Diagrammatic Representation of Proposed Mechanism of 
Megalin-Mediated Endocytosis of Polymyxin B in Renal Proximal Tubules 
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CHAPTER 6 
DISCUSSION 
 
      We are currently facing a shortage of viable treatment options against 
nosocomial/hospital-acquired infections caused by multidrug-resistant Gram-
negative pathogens. Due to prevailing multidrug-resistance among Gram-
negative bacteria, the persistent reliance on polymyxin B as a last viable 
treatment option is expected to accelerate worldwide. The clinical utility of 
polymyxin B is hindered mainly by its dose-limiting nephrotoxicity, which could be 
attributed to poor understanding of its pharmacokinetics, toxicodynamic profile, 
and underlying mechanisms of nephrotoxicity. Nonetheless, over the past 
decade, few noteworthy attempts have been made to characterize the 
pharmacokinetics, pharmacodynamic and nephrotoxicity of polymyxin B (Kwa et 
al., 2008; Tam, Cao, Ledesma, & Hu, 2011; Zavascki et al., 2008). Despite being 
available as a mixture of closely related analogs, the pharmacokinetic, 
pharmacodynamic and toxicological properties of polymyxin B are commonly 
reported as an aggregate of the individual components (Abdelraouf, He, 
Ledesma, Hu, & Tam, 2012; Sandri et al., 2013). Most pharmacokinetic studies 
reported so far have used total polymyxin B concentrations (sum of the 
chromatographic peak area of individual components) for drug quantification in 
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biological matrices. In these reports, the pharmacokinetic properties of individual 
aggregates were presumed to be the same as those of total polymyxin B, an 
assumption that is yet to be validated. Therefore, it remains critical to investigate 
whether individual components of polymyxin B exhibit similar pharmacokinetic 
characteristics (Tam, Hou, Kwa, & Prince, 2009). 
 
      In our investigation, we compared the pharmacokinetic profiles of the 
major components of polymyxin B in a rat model. We observed that the weighted 
average pharmacokinetic parameters (clearance and volume of distribution) 
derived using serum concentration for individual components were in reasonably 
close agreement (within two-fold range) with those derived directly from the total 
polymyxin B concentration. Furthermore, to compare systemic exposure in rats, 
area under the curve from 0 h to infinity AUC(0-∞) observed from total polymyxin B 
was 10.7 mg. h. L-1 which was akin to that derived from adding the AUC(0-∞) of 
individual polymyxin B components in the mixture which was 10.9 mg.h.L-1 
(Manchandani, Dubrovskaya, et al., 2016). Collectively, these findings suggest 
that the pharmacokinetics of various individual polymyxin B components were 
comparable. Furthermore, it appeared reasonable to use the summed 
concentrations of individual components (i.e. total polymyxin B concentrations) in 
pharmacokinetic studies to estimate overall drug exposure. Therefore; we used 
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summed concentration of polymyxin B components in our subsequent 
biodistribution and disposition studies. 
 
 To date, several attempts have been made to characterize the 
biodistribution and disposition profile of polymyxin B. Kunin et al. examined the 
biodistribution of polymyxin B in rabbits and observed that the distribution was 
non-uniform with higher accumulation in kidneys, liver, and muscles (Kunin & 
Bugg, 1971a, 1971b). Jacobson et al. investigated the distribution and binding of 
tritiated polymyxin B in a mouse model and observed higher accumulation in the 
kidneys (Jacobson et al., 1972). Our group also reported that polymyxin B was 
preferentially accumulated in rat kidneys with a prolonged residence time 
(Abdelraouf, He, et al., 2012). 
 
 In the present investigation, we provided additional insights into the overall 
biodistribution characteristics of polymyxin B. Despite using different animal 
species, methods for sample preparation and analysis, our biodistribution results 
were concordant with previously reported biodistribution results by Kunin et al. 
This suggested that polymyxin B distribution to different organs is not 
homogenous and the drug is preferentially accumulated in the kidneys. However, 
in contrast to previous studies by Kunin et al. (Kunin & Bugg, 1971a, 1971b), we 
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observed consistently low drug concentrations in the brain. The earlier studies by 
Kunin et al. used a non-specific microbiological assay to quantify the polymyxin B 
in various tissue homogenate rather than a sensitive, specific UPLC-MS/MS 
assay. Moreover, in these previous studies, a liquid-liquid extraction method was 
used for sample preparation; the drug was estimated separately in the organic 
and aqueous extraction layers in the bound and free form, respectively (Kunin & 
Bugg, 1971b). This procedure may have over-estimated the drug concentration 
as the final drug recovered from serum and tissue homogenate was found to be 
greater than the dose administered. Our brain tissue biodistribution results were 
in accordance with a recent review of clinical findings (Falagas, Bliziotis, & Tam, 
2007). Interestingly, we observed a higher concentration of polymyxin B in lung 
tissues as compared to serum at 6 h (but not at 3 h). This finding is in contrast to 
our previously reported low polymyxin B levels in the epithelial lining fluid (ELF) 
in mice (He, Gao, Hu, Chow, & Tam, 2013). Since lungs consist of several sub-
compartments (lung parenchyma, alveolar epithelium, macrophages, ELF and 
blood-alveolar barrier, etc.), assaying drug concentrations in the whole organ 
could be subjected to a high degree of variability. In summary, the present 
investigation provided valuable insights to the overall in vivo distribution 
properties of polymyxin B. We concluded that among all the organs evaluated; 
polymyxin B was highly accumulated in the kidneys, which may contribute to its 
nephrotoxic potentials. 
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 We further aimed at elucidating the intrarenal distribution pattern of 
polymyxin B. We have previously shown histological evidence that the polymyxin 
B-induced injury was mainly confined to the proximal tubular cells of the rat 
kidneys (Abdelraouf, Braggs, et al., 2012). In a mouse model, polymyxin B was 
found to be substantially accumulated in the renal proximal tubular cells (Yun, 
Azad, Wang, et al., 2015). Yun et al. also provided circumstantial evidence 
linking polymyxin B distribution to the site of renal injury. 
 
 In the present investigation, the sites of polymyxin B accumulation within 
the kidneys were identified at the cellular level using the same rat model. We 
evaluated drug accumulation in the multiple renal cell types (proximal convoluted 
tubules, distal convoluted tubules, and glomerulus) in a semi-quantitative fashion, 
establishing a more concrete association between site of drug accumulation and 
the site of renal injury. Among the different renal cell types evaluated, proximal 
tubular cells demonstrated the highest accumulation of polymyxin B. Collectively; 
these findings suggest that polymyxin B accumulation within the kidneys is 
heterogeneous, and is primarily confined to the proximal tubular cells. In 
conjunction with previous findings, it is likely that there is a direct link between 
the site of drug accumulation and injury at the cellular level within the kidneys. 
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These findings are expected to guide future investigations focusing on 
identifying/ elucidating the cellular apoptotic pathways as well as toxic 
mechanisms linked with polymyxin B-induced nephrotoxicity. 
 
 To delineate polymyxin B disposition characteristics in-depth, we explored 
various routes of elimination of polymyxin B. In contrast to an earlier study which 
reported that approximately 60% of the polymyxin B dose was recovered 
(Hoeprich, 1970), polymyxin B recovery from urine was reported to be very low in 
several recent studies. Abdelraouf et al. reported that less than 1% of polymyxin 
B was recovered in an unchanged form in the urine over 48 h after single 
intravenous dose (Abdelraouf, Braggs, et al., 2012; Abdelraouf, He, et al., 2012). 
Based on the urinary excretion data of polymyxin B available from 17 critically ill 
patients, Sandri et al. also reported the median urinary recovery to be 4.0% 
(range 1.0% - 17.4%) of the administered dose (Sandri et al., 2013). In line with 
previous findings, Zavascki et al. reported that less than 1% of the dose was 
recovered unchanged in urine samples following intravenous administration of 
polymyxin B in critically ill patients (Zavascki et al., 2008). 
 
In the present investigation, we observed that urine recovery of polymyxin 
B was substantially low. Our results from validated UPLC-MS/MS assay of the 
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urine samples after a single dose administration of polymyxin B indicated that 
less than 1% of the administered dose was recovered over 48 h in its parent 
form. Although these results corroborated previous findings on a low recovery of 
the drug in urine, the urinary disposition of any active metabolite remained 
unknown. We further confirmed that less than 5% of the administered dose (or 
pharmacologically active metabolites, if any) was recovered from urine over 48 h 
using a validated microbiological assay method. In addition to demonstrating a 
low urine recovery of polymyxin B, the use of a microbiological assay in this 
study provided additional evidence that renal excretion of the active metabolite(s) 
are unlikely.  A recent report by Nilsson et al. demonstrated the formation of 
amide hydrolytic adducts of polymyxin B in the renal tissue using high-resolution 
mass spectrometry imaging (Nilsson et al., 2015). This suggests that proteolytic 
degradation could be one of the potential pathways of in vivo biotransformation of 
polymyxin B. This could be one of the underlying factor for low urine recovery of 
polymyxin B in its parent form. However, further investigations are warranted to 
substantiate this finding.         
 
   Over the past decades, several noteworthy attempts have been 
made to advance our understanding of the nephrotoxicity associated with renal 
accumulation of polymyxins. A recent study by Azad et al. investigated the 
underlying mechanism of polymyxin B nephrotoxicity in the rat (NRK-52E) as well 
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as human (HK-2) kidney proximal tubular cell lines. Cellular apoptosis was 
identified to be a potential mechanism of polymyxin B-induced nephrotoxicity. It 
was reported that apoptosis was triggered via activation of the caspase pathway 
in a time and concentration-dependent fashion. The onset of polymyxin B-
nephrotoxicity was observed to be highly correlated to the renal drug 
concentration (Azad et al., 2013).  
 
   In the present investigation, we observed that polymyxin B dose was 
correlated to the renal drug concentration, which was further correlated to the 
onset of nephrotoxicity. The higher daily dose of polymyxin B was associated 
with a greater degree of drug accumulation in the renal tissues and subsequently 
manifested as a more rapid onset of nephrotoxicity. These findings were 
consistent with the previous results from our laboratory demonstrating the 
preferential renal accumulation and prolonged residence of polymyxin B in an 
animal model, and thereby predisposing the kidneys to the toxic effect of 
polymyxin B (Abdelraouf, Braggs, et al., 2012; Abdelraouf, He, et al., 2012; 
Manchandani, Zhou, et al., 2016). 
 
 The preferential intrarenal accumulation of polymyxin B could be one of the 
key factors attributed to its nephrotoxicity. Therefore, delineating the mechanism 
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of intrarenal drug uptake is fundamental to bridging the knowledge gap in current 
understanding of polymyxin B nephrotoxicity. Recently, few significant published 
literature investigating the involvement of transporters in renal uptake of 
polymyxin B have been reported. Suzuki et al. reported a significant decrease in 
the renal concentration of colistin in megalin-shedding rats which suggested the 
involvement of megalin in the renal drug accumulation (Suzuki et al., 2013). 
Although, the renal accumulation of polymyxin B was markedly reduced (nearly 
one-third as compared to control rats) in megalin-shedding rats but could not be 
completely abolished. This insinuated that transporters other than megalin could 
be involved in renal uptake of polymyxin B. Lu et al. also demonstrated the role 
of oligopeptide transporter-2 (PEPT-2) in the renal uptake of polymyxins in 
human embryonic kidney cell line (HEK-293). Furthermore, both polymyxin B and 
colistin were used as competitive inhibitors to block the renal uptake of 
radiolabeled glycine-sarcosine, a potential substrate of PEPT-2 transporter 
overexpressed in HEK-293 cell line (Lu et al., 2016).  
 
  The other promising feature of the our study involves delineating the 
possible role of an endocytic receptor [megalin or low-density lipoprotein-2 
(Lrp2)] in the renal accumulation of polymyxin B. Maleate was reported to disrupt 
the membrane association of megalin with the brush border epithelium in the 
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renal proximal tubular cells, which was earlier shown to induce shedding of 
megalin in rats (Suzuki et al., 2013). Additionally, we verified megalin-shedding 
by the quantitative recovery of megalin in urine and imaging of maleate-treated 
kidney sections. Electron microscopic examination of kidney sections revealed 
marked ultrastructural changes in the proximal tubules post maleate treatment. 
These results were consistent with those reported by Bergeron et al. (Bergeron, 
Mayers, & Brown, 1996). Maleate is also known to induce apical membrane-
associated transport defects in the renal proximal epithelial cells similar to those 
observed in Fanconi syndrome. Maleate-induced ultrastructural changes 
transiently disrupt the apical endocytic and recycling apparatus leading to 
accumulation of microvesicles in the proximal tubules (Norden et al., 2002). 
Therefore, the abundance of apical microvesicles in our microscopic images 
suggests that maleate might be involved in the inhibition of membrane recycling 
process, thereby inducing generalized transport defects similar to those observed 
in Fanconi syndrome. This finding corroborated the conclusions of Christensen et 
al., who previously demonstrated that maleate induces inhibition of lysozyme 
transport from the endocytic vacuoles to the lysosomes (Christensen, Gliemann, 
& Moestrup, 1992). Collectively based on these findings, we hypothesize that 
megalin is involved in the internalization of polybasic drugs (such as polymyxin 
B) by playing a crucial role in drug transport through endocytic recycling 
apparatus. 
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  Finally, we investigated the systemic/renal exposure of polymyxin B in 
megalin-shedding rats. Thematically, the tissue expression of megalin primarily 
corresponds to the renal proximal tubular epithelium in rats; we presumed that 
only renal exposure of polymyxin B would be affected and systemic exposure will 
remain unchanged upon induction of megalin-shedding in rats. Remarkably, our 
results indicated that polymyxin B concentration in renal tissue was attenuated by 
approximately 40% after maleate pre-treatment. However, the systemic drug 
exposure remained mostly unaltered in the megalin-shedding rats. This could 
primarily be attributed to the diminished availability of membrane-bound (i.e., 
functional) megalin in kidneys after pre-treatment with maleate. These findings 
suggested that preferential renal accumulation of polymyxin B could be reduced 
by disrupting relevant mechanism(s) of drug uptake, leading to possible delay in 
the onset of nephrotoxicity. We further performed the absolute quantification of 
individual components of polymyxin B in renal tissues for both control as well as 
maleate-treated rats. Our results indicated that the various polymyxin B 
components (PMB1, Ile-PMB1, PMB2, and PMB3) demonstrated comparable 
affinity towards renal megalin transporter. However, these results are further 
needed to be evaluated. 
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6.1  Potential Limitations of Present Research 
  There are several limitations to our investigation. The biodistribution and 
disposition properties of polymyxin B were investigated only after a single dose, 
further investigations to assess the steady-state pharmacokinetics, of polymyxin 
B after multiple doses are warranted.  
 
  With regards to intrarenal accumulation of polymyxin B, we successfully 
located the site of drug accumulation at the cellular level. However, for better 
resolution, future studies aimed at identifying the drug accumulation at 
subcellular/ organelle level are highly warranted. From the toxicity perspective, 
we could not delineate the polymyxin B-induced toxicity pathway that triggers 
cellular apoptosis in renal cells. In our future investigations, we need to evaluate 
the mechanisms of programmed cell death events in various cellular organelles 
induced as a result of prolonged residence of polymyxin B within renal cells.   
 
  Our investigation established a correlation between daily dose, renal drug 
exposure and the onset of polymyxin B-induced nephrotoxicity. We demonstrated 
that the higher daily dose of polymyxin B was associated with the greater drug 
accumulation in the renal tissues which further manifested as a more rapid onset 
of nephrotoxicity. Based on our results we projected that the same total daily 
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dose of polymyxin B, when administered on multiple days, would expedite the 
onset of drug-induced nephrotoxicity. We also observed that this preferential 
renal accumulation of polymyxin B could be attenuated by disrupting the megalin, 
a renal endocytic uptake transporter. Despite this evidence, we could not directly 
demonstrate the delay in onset of nephrotoxicity in megalin-shedding rats. This 
limitation was mainly attributed to the interference of megalin in the assessment 
of elevation in serum creatinine level which was an endpoint for nephrotoxicity 
onset. Owing to this limitation, the renal drug concentration was used as a 
surrogate marker for nephrotoxicity endpoint detection.  
 
  Furthermore, our preliminary results from the megalin-shedding rats 
established circumstantial evidence that megalin could be involved in the renal 
accumulation of polymyxin B. However, this conclusion was derived from an 
indirect and non-specific approach of disrupting the membrane-bound megalin 
using a chemical agent (sodium maleate). Therefore, there is a need to validate 
these findings using more direct methods. For future studies, we plan to use the 
specific molecular tools (such as siRNA-mediated gene silencing), use of the 
megalin knockout animal model to further corroborate the role of megalin in the 
renal accumulation of polymyxin B. 
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CHAPTER 7 
FUTURE DIRECTIONS 
 
 
        In summary, our results indicate that various individual components of 
polymyxin B exhibit comparable pharmacokinetic profiles. We have successfully 
established an overall biodistribution profile of polymyxin B in vivo using a rat 
model; polymyxin B demonstrated preferential accumulation and prolonged 
resistance in renal tissues. Furthermore, our results indicated that among various 
renal cell types (proximal tubules, distal tubules and glomerulus), proximal 
tubules are the primary anatomical sites with highest accumulation of polymyxin 
B. Concerning drug disposition, our urinary recovery data indicated that less than 
1% of the administered dose was eliminated in the parent form. Furthermore, 
only less than 5% of the administered dose was eliminated in the 
pharmacologically active form (including metabolites, if any) through the urinary 
route.  
 
        Despite our efforts, we lack information about the comprehensive 
metabolic and biliary disposition profile of polymyxin B. We further aim to provide 
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insights into the mechanisms of cell uptake as well as cell toxicity. We intend to 
investigate the in-depth metabolic pathways of polymyxin B using in vitro as well 
as in vivo models. With regards to the drug disposition studies, we plan to assess 
the biliary disposition of polymyxin B after single as well as multiple dosing for 
longer duration in rats. Our research has successfully delineated that proximal 
convoluted tubules are the anatomical site of highest intrarenal drug 
accumulation and locus of polymyxin B-induced renal injuries. In the view of 
polymyxin B mechanistic studies pertaining to the investigation of intrarenal 
uptake and cellular toxicity, we propose to conduct series of uptake experiments 
and cytotoxicity assays using immortalized human proximal tubular (HK-2) cell 
line. 
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7.1    Aim 1: To investigate in vitro and in vivo metabolism of polymyxin B  
7.1.1     Working Hypothesis 
    Our biodistribution and disposition study could not account for the 
majority of the administered dose in vivo. Moreover, the polymyxin B recovery 
was very low in urine (as a pharmacologically active form) and in bile (as parent 
form). Based on these findings, we hypothesize that polymyxin B might undergo 
hepatic drug metabolism. 
7.1.2     Justification and Feasibility 
7.1.2.1  Review of Relevant Literature 
 Nilsson et al., demonstrated the simultaneous distribution of polymyxin B 
and its metabolites in the rat kidney cross-section using mass spectrometry 
imaging and liquid extraction surface analysis (LESA). The study reported the 
biotransformation of polymyxin B into smaller peptide fragments formed as a by-
product of amide hydrolysis. Moreover, biotransformation into demethylated and 
oxidative metabolites of parent polymyxin B was also reported (Nilsson et al., 
2015). Since oxidation and demethylation are cytochromes P-450 mediated 
biotransformations, we performed an in vitro polymyxin B metabolism study using 
primary mouse hepatocytes. Midazolam was used as a control for the 
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experiment. We observed approximately 80% reduction in the parent drug 
concentration over 24 h of incubation with primary hepatocytes.  
 
7.1.2.2   Preliminary Results 
 Our preliminary results obtained from LC-MS/MS analysis of rat urine 
after polymyxin B dosing using Qtrap 5500 UPLC-MS/MS (enabled with 
lightsight® and IDA wizard feature) system. Our results demonstrated the 
presence of oxidative, demethylated and glucuronide metabolites of polymyxin B. 
These results suggested the oxidation (at three different sites to form tri-oxidative 
metabolite); decarboxylation; demethylation and glucuronidation could be the 
most probable in vivo polymyxin B biotransformation pathways.  
 
The preliminary results from an in-vitro metabolism study with primary 
mouse hepatocytes revealed that there was approximately 80% reduction in the 
intracellular concentration of parent polymyxin B2 as shown in Figure 7.1. The 
results of polymyxin B concentration estimated at regular time intervals after 
incubating with primary hepatocytes are summarized in Table 7.1. This 
insinuated the possibility of cytpchrome-450 mediated drug metabolism of 
polymyxin B.  
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Table 7.1: Intracellular Concentration of Polymyxin B in the Primary 
Hepatocyte Cells Culture 
Incubation time (h) Intracellular concentration (µg/ml) 
Polymyxin B2 Midazolam 
1 0.045 6.622 
4 0.021 3.964 
8 0.004 3.941 
24 0.008 0.666 
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Figure 7.1: In-vitro Metabolism of Polymyxin B2 using Primary Hepatocyte 
Cell Culture 
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Figure 7.2: Metabolic Profiling of Polymyxin B in Rat Urine using IDA 
Wizard and Lightsight® Feature of Qtrap UPLC-MS/MS  
A. Parent Polymyxin B Peak in Blank Rat Urine 
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B. Peak Representing Loss of Glucuronide and Decarboxylation in Rat 
Urine Dosed with Polymyxin B 
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C. Peak Representing Tri-Oxidation in Rat Urine Dosed with Polymyxin B 
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D. Peak Representing Loss of Glucuronide and Demethylation in Rat 
Urine Dosed with Polymyxin B 
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Figure 7.3: Chromatogram for Pre-and-Post Polymyxin B Dosed Rat Urine 
using MRM Feature of Qtrap UPLC-MS/MS  
A.  Pre-Dose Urine    B.   Post-Dose Urine 
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7.1.4     Research Design 
7.1.4.1  Antimicrobial Agent 
   Polymyxin B sulfate (USP) powder will be purchased from Sigma-Aldrich 
(St. Louis, MO). Prior to each experiment, the drug will be reconstituted and 
diluted to the desired concentrations with normal saline. The reconstituted drug 
solutions will be stored at -80ºC until analysis. 
 
7.1.4.2 Animals 
             Female Sprague-Dawley rats (225-250g) (Harlan, Indianapolis, IN, USA) 
will be used. The rats will receive food and water ad libitum. In selected 
experiments, jugular veins of selected animals will be cannulated to facilitate 
intravenous drug administration. Male C58BL/6 mice will be obtained from 
(Harlan Houston, TX). The mice will have access to regular rodent chow and 
water ad libitum. All animals will be maintained in a 12 h dark/light cycle and a 
temperature-and-humidity-controlled environment and cared for in accordance 
with the highest humane and ethical standards, as approved by Institutional 
Animal Care and Use Committee (IACUC) of the University of Houston. 
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7.1.4.3  In vitro Metabolism Studies 
  Primary mouse hepatocytes will be isolated from C57BL/6 mice using the 
two-step collagenase perfusion technique with slight modifications as described 
previously (Li et al., 2002; Ghose et al., 2004, 2008, 2009, 2011). Briefly, after 
digestion, the liver will be excised and transferred to a sterile 50 ml conical tube 
containing William’s medium E supplemented with 1% streptomycin, glutamine, 
0.1% gentamycin, glucagon and 10% fetal bovine serum. The hepatocytes will be 
then purified using a percoll gradient and washed twice; later screened for 
viability using the trypan blue exclusion technique. The cells with the viability of 
more than 90% will be further used for these studies. Cells will be plated at a 
density of 500,000 cells per well in six-well Primaria plates (BD Biosciences, San 
Diego, CA, U.S.A) and allowed to attach for 4h. Cells will be maintained for 48h 
with daily change of medium.  
 
The cells will be incubated with serum-free William’s medium E two hours 
prior to treatment. The cells will be incubated with polymyxin B (USP mixture) at 
varying final concentrations of 0.5, 1, 2, 4, 8 µg/ml in the culture well for 1, 2, 4, 8 
and 24 h. After pretreatment with polymyxin mixture for a specific time, the 
reaction will be stopped with the solution (100 µl) of acetonitrile in phenacetin (1 
µg/ml). Midazolam will be used as positive control and cells will be treated with 2 
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µM of midazolam in the similar fashion. The cells will further be lysed using lysis 
media and by passing through insulin syringe several times. The supernatants 
will be collected and stored in -80° until further analysis.  
 
7.1.4.4 UPLC-MS/MS Based Metabolic Profiling of Polymyxin B 
   The rats (n=2) will be housed individually in separate metabolic cages to 
facilitate urine collection. Later, rats will be cannulated at jugular vein to facilitate 
drug administration. Blank urine will be collected from each rat prior to the 
administration of a single dose of polymyxin (3 mg/kg). The blood will be 
collected at 1, 2, 4, 8, 24 h time points through jugular vein catheter. Pre-dose 
and post-dose urine will be spun down to remove particulate matter and stored in 
aliquots at -80ºC until analysis. For metabolic profiling in bile, the rats will be 
cannulated at jugular vein as well as at bile duct. Pre-dose (blank) bile will be 
collected for 30 min followed by the collection of bile for 8 h post single dose (3 
mg/kg) of polymyxin B dosing. 
 
Prior to analysis, sample (serum, urine, and bile) will be thawed and 
processed for extraction with 5% TCA to precipitate protein as described in 
chapter 3. Additionally, for urine and bile samples, the supernatant after protein 
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precipitation will be loaded into the solid-phase extraction cartridges (Oasis HLB 
1cc cartridges, 30 µm), preconditioned with 1m of methanol and 1 x 2 ml of 
water. After loading the urine samples, the cartridges will be washed with water 
followed by eluting solvent (0.1% formic acid in water: acetonitrile, 50:50) 
mixture. The eluent will be collected, diluted 10 times with water and then 
injected into UPLC/MS-MS for metabolic profiling.  
 
ULPC-MS/MS Qtrap 5500 system equipped with lightsight® software 
functionality will be used for metabolite identification. The lightsight® software 
was designed to create compound-specific predicted multiple reactions 
monitoring-independent data acquisition for polymyxin B which will enable 
precise identification of metabolites. 
 
 
7.1.5 Expected Outcome 
 We expect to see the oxidative, demethylated and glucuronide 
metabolites of polymyxin B. We anticipate that polymyxin B will also undergo 
amide hydrolysis to form smaller peptides. 
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7.1.6   Potential Problem and Alternate Strategy 
   Since we are using primary hepatocytes as our in vitro model to study 
metabolism, our metabolism information is only limited to the hepatic metabolism 
of polymyxin B. We might not be able to capture the information if polymyxin B 
undergoes renal metabolism. An alternative strategy would be to use S9 
fractions/microsome derived from the rat kidney or the primary culture of isolated 
proximal convoluted tubules from rats as our future in vitro model. This would 
give us insights on the metabolic profile of polymyxin B via renal drug 
biotransformation. 
 
7.2 Aim 2: To investigate the biliary disposition of polymyxin B  
Finally, to the best of our knowledge, the present study is the first to 
examine the biliary excretion of polymyxin B. We detected all four major 
polymyxin B components in the bile over 4 h. To further substantiate this 
observation, we designed a multiple-dose (single dose of 3 mg/kg up to 10 
consecutive days) biliary drug disposition study to further quantify polymyxin B in 
bile. Despite our efforts in quantifying all four major components of polymyxin B 
in bile, we could only account for the biliary excretion of the parent drug. Our 
results indicated a very low drug recovery; less than 1% of the parent drug was 
quantified over 24 h in bile. The major limitation of this study was that validated 
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UPLC-MS/MS assay in bile could only account for the parent form of the drug. 
Besides, the bile components and salts offered a high level of interference in the 
microbiological assay. Therefore, the drug cannot be accurately quantified. 
Nonetheless, we could not account for the majority of the administered dose in 
our biodistribution/disposition study.  
 
Despite our efforts in quantifying all four major components of polymyxin B 
in bile, we could only account for the biliary excretion of the parent drug. 
Furthermore, many questions related to hepatic/renal drug metabolism and 
subsequent nonrenal excretion of its metabolites remain unanswered. Therefore, 
more rigorous studies are still needed to establish various facets such as in vivo 
metabolism profile and renal handling of polymyxin B. Future studies in our lab 
will aim at identifying as well as quantifying the major metabolites of polymyxin B. 
Currently, studies are ongoing in our lab to develop a validated UPLC-MS/MS 
assay which can reliably detect/quantify polymyxin B metabolites in bile. This will 
further delineate the disposition of drug metabolites in bile. Moreover, we also 
aim at investigating the renal uptake of polymyxin B using various mammalian 
cell lines. In conclusion, biliary excretion could be one of the possible routes of 
elimination for polymyxin B metabolites, which should be explored further. 
 
 144 
 
 
7.2.1    Working Hypothesis 
   Our preliminary results on urine recovery of polymyxin B demonstrated 
that less than less than 1% of the administered dose was eliminated unchanged 
in the urine over 48 h (Abdelraouf, He, et al., 2012). Furthermore, we 
demonstrated that less than 5% of the administered dose was eliminated in the 
pharmacologically active form (metabolite, if any) through the urinary excretion 
route (Manchandani, Zhou, et al., 2016). These results insinuate that polymyxin 
B is most likely to be disposed via non-renal elimination pathways. Based on 
these findings, we hypothesize that polymyxin B could be eliminated via biliary 
route. 
 
 
7.2.2     Justification and Feasibility 
7.2.2.1 Review of Relevant Literature 
   We were able to successfully detect the four major components of 
polymyxin B in bile (Manchandani, Zhou, et al., 2016). Moreover, our preliminary 
metabolism studies predicted the presence of a glucuronide metabolite in the rat 
urine. Therefore, we further aim at developing a method to quantify a glucuronide 
metabolite in the bile. 
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7.2.2.2   Preliminary Results 
    Our results indicated that less than 1% of polymyxin B dose was 
excreted unchanged in bile 4 h after a single dose of polymyxin B as shown in 
Table 7.2. The bile could only be collected only until 4 h after drug administration 
due to limitation of our in-house surgical procedure as rats could not survive 
longer than 4 h. Initially, we suspected that survival of rats might be 
compromised due to lack of fluid replenishment after bile collection at every hour. 
To test this speculation we measured the volume of bile collected after every 
hour. Much to our surprise, the volume of bile collected every hour was roughly 
same (approximately 400 µl). However, to eradicate this limitation, we plan to 
further investigate biliary disposition of polymyxin B using surgically-modified rats 
which would facilitate bile collection for 24 h or longer duration. 
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Table 7.2: Biliary Disposition Profile of Parent Polymyxin B after Single Dosing 
 Rat ID Amount of polymyxin 
B administered (µg) 
Cumulative amount of 
polymyxin B in bile (µg) 
% dose excreted 
unchanged in bile 
1 745.92 2.74 0.37 
2 716.70 3.60 0.50 
3 716.70 3.34 0.47 
4 744.50 1.94 0.26 
5 744.50 2.18 0.29 
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Figure 7.4: Biliary Disposition Profile of Parent Polymyxin B after Single 
Dosing 
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7.2.3     Research Design 
7.2.3.1  Antimicrobial Agent 
   Polymyxin B sulfate (USP) powder will be purchased from Sigma-Aldrich 
(St. Louis, MO). Prior to each experiment, the drug will be reconstituted and 
diluted to the desired concentrations with normal saline. The reconstituted drug 
solutions will be stored at -80ºC until analysis. 
 
 
7.2.3.2 Animals 
              Female Sprague-Dawley rats (225-250g; Harlan, Indianapolis, IN, USA) 
will be used as our in vivo model to study drug disposition in bile. In selected 
experiments, jugular veins of selected animals will be cannulated to facilitate 
intravenous drug administration. The animals will receive food and water ad 
libitum and will be maintained in a 12 h dark/light cycle and a temperature-and-
humidity-controlled environment. All animals will be cared for in accordance with 
the highest humane and ethical standards, as approved by Institutional Animal 
Care and Use Committee (IACUC) of the University of Houston. 
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7.2.3.3 Biliary disposition of polymyxin B and its metabolites in rats 
             Once the metabolites of polymyxin B are identified, we would further 
assess the biliary disposition of parent as well metabolites at steady state. The 
steady state will be achieved by dosing polymyxin B for 11 consecutive days. 
Rats will undergo bile duct cannulation to collect the bile over 24 h post-dosing. 
The parent drug and the metabolites will be quantified in the bile using a 
validated UPLC-MS/MS method. 
 
7.2.4 Expected Outcome 
 We expect to account for the majority of the administered dose 
eliminated in the bile either as parent drug or as its glucuronide metabolite. 
 
7.2.5 Potential Problem and Alternate Strategy 
    One of the potential problems could be the low recovery of parent drug 
and metabolites in the bile. Under such circumstances, we could not establish a 
mass balance between dose administered and amount eliminated. This may 
warrant investigating drug disposition in feces. 
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7.3  Aim 3: To investigate in vitro cell uptake study of polymyxin B  
 We have concluded from our previous study that polymyxin B-induced 
injuries were primarily observed in the proximal tubules (Abdelraouf, Braggs, et 
al., 2012). Furthermore, extensive accumulation seen in these renal cell types 
established that the site of accumulation and site of drug-induced injury is 
identical (Manchandani, Zhou, et al., 2016). Therefore, we propose to further 
assess the mechanisms of in vitro cellular uptake and cellular toxicity due to 
prolonged polymyxin exposure using immortalized human renal proximal tubular 
cell line. 
 
7.3.1  Working Hypothesis 
  A previous study from our lab has demonstrated that the intracellular 
uptake of polymyxin B in proximal tubular cells is an active and saturable 
process. It has been reported that the polymyxin B internalization/uptake in 
kidneys is mediated via an apical membrane-bound uptake system (Abdelraouf, 
Chang, Yin, Hu, & Tam, 2014). We have also demonstrated in a rat model that 
this uptake process can be disrupted chemically by using sodium maleate 
(Manchandani et al., 2016). Maleate is known to induce transient ultrastructural 
changes in the membrane localization of megalin on the renal brush border 
epithelium, rendering it non-functional for uptake of drugs and endogenous 
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ligands (Bergeron et al., 1996). Based on these relevant facts, we hypothesize 
that polymyxin B accumulation within renal cells is mediated through megalin, a 
membrane-bound endocytic receptor (Lrp2/ gp330). Therefore, to elucidate the 
role of megalin we propose to conduct in vitro cell uptake and cytotoxicity 
experiments of polymyxin B using HK-2 cells with varying pretreatment 
concentrations of sodium maleate. 
 
7.3.2    Justification and Feasibility 
73.2.1   Review of Relevant Literature 
   Megalin is 600 kDa glycoprotein and endocytic receptor located on the 
brush border epithelium of renal proximal epithelium cells. A previous study 
reported the involvement of megalin in the internalization of polybasic drugs such 
as polymyxins, gentamicin, and amikacin within kidneys (Moestrup et al., 1995). 
Colistin, a closely related analogue of polymyxin B, both structurally and 
pharmacologically, exhibits a high affinity towards megalin (Suzuki et al., 2013).  
  
7.3.2.2   Preliminary Results 
   We performed in vitro cytotoxicity assay (MTT assay) using an 
immortalized HK-2 cells lines (Manassas, VA). In our treatment group, the cells 
 152 
 
 
were incubated first with sodium maleate (Sigma-Aldrich, St. Louis MO) for 24 h 
at a final concentration of 5µg/ml in each well, followed by incubation with varying 
concentrations of polymyxin B (3.125 – 100 µg/ml) for 48 h. However, in the 
control group, the cells were only incubated with varying concentrations of 
polymyxin B for 48 h. After pretreatment, the cell viability was measured by MTT 
assay as described previously (Huang et al., 2015). 
 
Our results indicated that there was no significant difference in the cell 
viability of HK-2 cells in the control and treatment group as shown in Table 7.3. 
These results indicated that 5 µg/ml of sodium maleate did not alter the 
mitochondrial activity; therefore, no major changes were observed in % cell 
viability between the control and the treatment group. We further estimated % 
cell viability with varying concentrations of sodium maleate as indicated in Table 
7.4. Our result indicated that the cells retained their viability up to approximately 
99% even when the concentration of sodium maleate exposed was increased 
100 times (500 µg/ml) as compared to previous concentration (5 µg/ml). 
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Table 7.3: MTT Assay of Polymyxin in the using HK-2 Cells 
 
Concentration of  
polymyxin B (µg/ml) 
% Cell viability 
Control group Treatment group (pre-
treatmentnt with sodium 
maleate, 5 µg/ml) 
3.125 98.12 98.58 
6.25 97.22 96.02 
12.5 74.95                     86.29 
25 41.96 57.03 
50 21.57 21.31 
100 14.82 13.64 
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Table 7.4: MTT Assay with Varying Concentrations of Sodium Maleate 
using HK-2 Cells 
 
Concentration of  polymyxin B (µg/ml) % Cell viability 
62.5 107.46 
125 108.95 
250 109.09 
500 98.86 
1000 81.18 
2000 48.65 
 
 
7.3.3     Research Design 
7.3.3.1 Antimicrobial Agent 
  Polymyxin B sulfate (USP) powder will be purchased from Sigma-Aldrich 
(St. Louis, MO). Prior to each experiment, the drug will be reconstituted and 
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diluted to the desired concentrations with normal saline. The reconstituted drug 
solutions will be stored at -80ºC until analysis. 
 
7.3.3.2 HK-2 Cell Culture 
  HK-2 cells (ATCC CRL-2190, Manassas, VA) will be grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum, 0.02% 
epidermal growth factor (EGF), 2 mM glutamine, 50 U/ml penicillin, 50 pg/ml 
streptomycin and 1% non-essential amino acids (Thermoscientific, Waltham, 
MA). The cells will first be seeded in 96-well plate at the density of 5000 cells/well 
and allowed to grow for 2-3 days. The media will be replaced, and later the cells 
will be maintained in 10% DMEM/F12 media supplemented with 10% fetal bovine 
serum, 100 U/ml penicillin, 100 g/ml streptomycin, 100 g/ml neomycin and 1-2 g 
of sodium bicarbonate (Thermoscientific, Waltham, MA). The pH of the media will 
be adjusted to 7.2 either by 0.1N NaOH or HCl (Sigma-Aldrich, St. Louis, MO). 
The cells will be seeded on a 96-well plate maintained at 37ºC and 5% CO2 
atmosphere with a density of 4000 cells/well. The cultures will be grown to 
approximately 80-90% confluency which usually takes 1-2 days. After attaining 
confluence, the splitting of the cells will be achieved by adding 5ml of PBS buffer 
supplemented with trypsin. The plates will be left undisturbed for 5 min and then 
scrapped to remove the cells. The cells will be centrifuged at 300 X g for 5 min 
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and split into 3 plates. Each plate will be added with 10 ml of PBS buffer, and the 
experiment will be performed in triplicates. 
 
7.3.3.3 Treatment Procedure 
   The HK-2 cells will be grown at 37ºC in a humidified incubator under an 
atmosphere of 95% air and 5% CO2; maintained at pH 7.4. To determine the role 
of megalin in cellular uptake of polymyxin B, we used the specific molecular tool 
such as megalin siRNA (Santa Cruz Biotechnology, Dallas, Texas) to silence/ 
knock down the megalin gene/ protein function in HK-2 cells. The cells will then 
be transfected with either 10 µM of 19-25 nucleotide megalin siRNA or 4 µg/well 
of scrambled megalin siRNA as described previously (X. C. Li & Zhuo, 2014). 
The specificity and effectiveness of these target-specific megalin siRNAs on the 
megalin knockdown has been previously reported elsewhere (M. Li, 
Balamuthusamy, Simon, & Batuman, 2008). Fresh DMEM medium will be added 
to the cells, and subsequently, the cell will be treated with escalating 
concentrations of polymyxin B (3.125-100 µg/ml) for 48 h. For the control group, 
the entire procedure will remain same except the omission of the transfection 
with megalin siRNA. The cells will then be lysed using ultrasonication and 
passing through insulin syringe. The intracellular concentration of polymyxin B 
would be further assessed in both the groups using validated UPLC-MS/MS 
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assay. To evaluate % cell viability in both the groups, we would perform MTT 
assay on control as well as treated cells. Furthermore, we expect to establish a 
correlation between cell viability and intracellular concentration of polymyxin B. 
 
7.3.4 Expected Outcome 
 We expect to see an attenuated polymyxin B uptake into the HK-2 cells 
transfected with megalin siRNA as compared to the control group. We anticipate 
that cell viability will be correlated to the intracellular uptake of polymyxin B; 
revealing an inverse association. We anticipate observing the higher levels of 
polymyxin B within control cells as compared to pretreated cells which will 
indicate a greater degree of intracellular drug uptake in control cells. This will 
subsequently result in lower cell viability and would show aggravated levels of 
toxicity in the control cells as compared to the pretreated cells.  
  
7.3.5 Potential Problem and Alternate Strategy 
 One of the anticipated problems could be the lack of significant difference 
in the % cell viability of control and treatment group using MTT assay. Under 
such circumstances, we may need a more design a more specific mitochondrial 
toxicity assay on the isolated rat primary proximal tubular cell line. Other potential 
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problems could be the lack of significant difference in the intracellular polymyxin 
B concentrations between control and treatment group. This could be due to 
compensation of renal drug uptake by the secondary transport mechanism if any. 
Polymyxin B is a polycationic drug, presumed to be a ligand for carnitine/organic 
cation transporter-1 (OCTN1/SLC22A4) (Ma et al., 2009) or oligopeptide 
transporter-2 (PEPT-2) (Lu et al., 2016). If we observe potential compensation by 
other transport mechanisms, we might need to re-examine intracellular uptake of 
polymyxin B using either cell lines overexpressing OCTN1/PETP-2 or genetically 
modified [OCTN1 gene (-/-)]/   [PEPT-2 gene (-/-)] mouse model. 
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